

09/889746

PATENT

DOCKET NO. BM45352

518 Rec'd PCT/PTO 20 JUL 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**BOX PCT/DO-EO**

Commissioner for Patents
Washington, D.C. 20231

"Express Mail" mailing label number EL 742 362 322 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated above and addressed to: Commissioner of Patents, Washington, DC 20231, on July 20, 2001.


Colleen Hanagan

NATIONAL STAGE APPLICATION TRANSMITTAL LETTER
APPLICATION FILING UNDER 35 U.S.C. § 371

Transmitted herewith for filing is the patent application of:

Inventor(s)/Applicant(s): Ruelle, Jean-Louis
International Application No.: PCT/EP00/00428
International Published Appln. No.: WO 00/43519
International Filing Date: 19 January 2000
Priority Filing Dates: 22 January 1999, 28 January 1999,
29 January 1999, 15 February 1999 &
16 February 1999
Thirty Month Date: 22 July 2001
Title: "NOVEL COMPOUNDS"

1. **THIS NEW APPLICATION IS A NATIONAL STAGE APPLICATION UNDER PCT, CHAPTER II WITH A REQUEST FOR EXAMINATION WITHOUT DELAY TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US).**

- ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. § 371;
☐ This is a **SECOND** or subsequent submission of items concerning a filing under 35 U.S.C. § 371.

2. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).

JC18 Rec'd PCT/PTO 20 JUL 2001

3. A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.

4. Enclosed items are required for filing under 37 CFR § 1.53(b) and § 1.494(b) or § 1.495(b):

- ☒ One copy of International Publication No. WO 00/43519
- (a) ☒ is transmitted herewith (**required only if not transmitted by the International Bureau**)
- (b) ☐ has been transmitted by the International Bureau
- (c) ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)

Fees

☒ The basic national fee set forth in 37 CFR § 1.482 - International Preliminary Examination Fee not paid to USPTO but International Search Report prepared by the EPO or JPO - **\$860.00**

- ☒ Claims in Excess of 20 (1 @ \$18.00)
- ☐ Independent Claims in Excess of 3 (@ \$80.00)

5. Further enclosed are:

- ☒ One copy of International Preliminary Examination Report.
- ☐ One copy of International Search Report.
- ☐ One copy of Written Opinion.
- ☐ One copy of PCT Request as filed.
- ☐ One copy of Chapter II Demand as filed.

6. ☐ A translation of the International Application into English (35 U.S.C. § 371(c)(2))

7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3))

8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3))

9. Still additional papers enclosed:

- ☐ Assignment with Assignment Recordation Form Cover Sheet
- ☐ Verification Statement Claiming Small Entity Status
- ☐ Declaration or oath is enclosed executed by the inventor
- ☐ An Information Disclosure Statement under 37 CFR § 1.97 and § 1.98
- ☒ Return Acknowledgment Postcard

JC18 Rec'd PCT/PTO 20 JUL 2001

10. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
- A. Enclosed are:
- (a) ☐ Computer Readable Copy of the Sequence Listing
- (b) ☐ Paper Copy (identical to Computer Readable Copy) of the Sequence Listing
- B. ☐ Enclosed is a paper copy of the Sequence Listing. This paper copy and a Computer Readable Form thereof are identical with the Computer Readable Form in another application of the Applicant which is fully identified as follows:
- U.S. Application No.: @@
- Filed: @@
- Attorney Docket No.: @@
- which is believed to comply with the rules set forth in 37 CFR § 1.821 et. seq. Applicants requests pursuant to 37 CFR § 1.821(e) that this Computer Readable Form be used in the present application. **Please TRANSFER the sequence listing from the parent to this application.**
- C. ☐ Statement under 37 CFR § 1.821(f): **The information recorded in computer readable form is identical to the written Sequence Listing.**
- D. ☐ Statement under 37 CFR § 1.821(g) (required when Sequence Listing not submitted at the time of filing under 35 U.S.C. §111(a)) or 37 CFR §1.821(f) (required when Sequence Listing not submitted at the time of filing under the Patent Cooperation Treaty): **The submission of the Sequence Listing includes no new matter.**
- E. ☐ Amendment: Please enter the Sequence Listing into the application.

11. **Preliminary Amendment**

Prior to calculation of fees, kindly enter:

- ☒ Preliminary Amendment submitted herewith
- ☐ do not enter Preliminary Amendment

09/889746

PATENT

DOCKET NO. BM45352

JUL 20 2001
PCT/PTO 20 JUL 2001

12. The correspondence address for this application is the Customer No. provided below:

Insert Bar Code Label Here:



25308

PATENT TRADEMARK OFFICE

13. Fee payment being made at this time is enclosed:

* Basic filing fee (\$860.00)	860.00
* Claims in Excess of 20	18.00
* (1 @ \$18.00)	
Independent Claims in Excess of 3	00.00
(@ \$80.00)	
* Total Fees enclosed:	<u>\$878.00</u>

14. The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Account No. 50-0258. This letter is filed in duplicate for accounting purposes.

Respectfully submitted,

Eric A. Meade
Registration No. 42,876
for
Allen Bloom
Registration No. 29,135
Attorney for Applicants

DECHERT
Princeton Pike Corporate Center
PO Box 5218
Princeton, New Jersey 08543-5218
Allen Bloom (609) 620-3214
Eric A. Meade (609) 620-3248
Fax: (609) 620-3259
Attn.: Allen Bloom, Esq.
(609) 620-3214

C:\WIN98\TEMP.2GZJ01!.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : International Application No.: PCT/EP00/00428
Ruelle : I.A. Filing Date: 19 January 2000
Serial No.: 09/889,746 : Priority Dates: 22 January 1999, 28 January
: 1999, 29 January 1999, 15 February 1999 and
: 16 February 1999
For: Novel Compounds :

Commissioner for Patents
Box PCT
Washington, DC 20231

**RESPONSE TO NOTIFICATION TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Sir:

This is in reply to the communication mailed 20 August 2001 from the Patent Office, entitled "Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures." A copy of the Notice is enclosed.

Submitted herewith is the "Sequence Listing" in computer readable form in accordance with the requirements of 37 CFR §§ 1.821-1.825.

STATEMENT

Applicant hereby states that the enclosed CRF diskette submitted herewith is identical to the paper copy of the "Sequence Listing" contained in the copy of International Publication No. WO 00/43519 which was submitted on July 20, 2001 for filing with the US Patent Office and contains no new matter.

Respectfully submitted,

Arthur E. Jackson
Registration No. 34,354
Attorney for Applicant

DECHERT
4000 Bell Atlantic Tower
1717 Arch Street
Philadelphia, PA 19103-2793
Fax: (609) 620-3259
Attn: Eric A. Meade
(609) 620-3248


00889746-1
PCT 94/26860


Docket No. BM45352

Serial No. 09/889,746

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being caused to be deposited on the date shown below with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Box PCT, Washington, D.C. 20231.


Colleen Hanagan


Date

120903.1.07

09/889,746 PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ruelle
Docket No.: BM45352
Serial No.: Unknown
Filed: Herewith

Group Art Unit No.: Unknown
Examiner: Unknown

For: Novel Compounds

PRELIMINARY AMENDMENT

Sir:

Applicant respectfully requests that this Preliminary Amendment be entered in this case before the calculation of fees and before examination of the subject application.

In the Claims:

Please delete the claims of the application as filed in the PCT and substitute therefor:

25. An isolated polypeptide comprising a member selected from the group consisting of
- (a) an amino acid sequence matching one of SEQ ID NOs:2 (BASB047), 4 (BASB054), 6 (BASB068), or 8 (BASB069);
 - (b) an immunogenic polypeptide comprising a fragment sequence of at least 15 amino acids that matches an aligned contiguous segment of one of SEQ ID NOs: 2, 4, 6, or 8;

wherein the isolated polypeptide, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell immune response to a polypeptide having the sequence of one of SEQ ID NOs:2, 4, 6, or 8.

26. An isolated polynucleotide encoding a polypeptide of Claim 25 or the full complement to the isolated polynucleotide.

27. The isolated polypeptide of claim 25, wherein the polypeptide is according to (a).

28. An isolated polynucleotide encoding a polypeptide of Claim 27 or the full complement to the isolated polynucleotide.

29. The isolated polypeptide of claim 25, wherein the polypeptide is according to (b).
30. An isolated polynucleotide encoding a polypeptide of Claim 29 or the full complement to the isolated polynucleotide.
31. The isolated polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises at least 20 amino acids.
32. The isolated polypeptide of Claim 25 wherein the isolated polypeptide of (a) consists of one of SEQ ID NOs:2, 4, 6, and 8.
33. An isolated polynucleotide encoding a polypeptide of Claim 32 or the full complement to the isolated polynucleotide.
34. A process for expressing the polynucleotide of Claim 33 comprising transforming a host cell with an expression vector comprising the polynucleotide and culturing the host cell under conditions sufficient for expression of the polynucleotide.
35. A fusion protein comprising the isolated polypeptide of Claim 25.
36. An isolated polynucleotide comprising the polynucleotide of one of SEQ ID NOs:1, 3, 5, or 7.
37. An isolated polynucleotide segment comprising a polynucleotide sequence or the full complement of the entire length of the polynucleotide sequence, wherein the polynucleotide sequence hybridizes to the full complement of one of SEQ ID NOs:1, 3, 5, or 7 minus the complement of any stop codon, wherein the hybridization conditions include incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml denatured, sheared salmon sperm DNA, followed by washing in 0.1x SSC at 65°C; and, wherein the polynucleotide sequence is identical to one of SEQ ID NOs:1, 3, 5, or 7 minus any terminal stop codon, except that, over the entire length corresponding to one of

SEQ ID NOs:1, 3, 5, or 7 minus any terminal stop codon, n_n nucleotides are substituted, inserted or deleted, wherein n_n satisfies the following expression

$$n_n \leq x_n - (x_n \cdot y)$$

wherein x_n is the total number of nucleotides in SEQ ID NOs:1, 3, 5, or 7 minus any terminal stop codon, y is at least 0.95, and wherein any non-integer product of x_n and y is rounded down to the nearest integer before subtracting the product from x_n ; and wherein the polynucleotide sequence detects *Neisseria meningitidis*.

38. An expression vector comprising the isolated polynucleotide of Claim 26.
39. A host cell transformed with the expression vector of Claim 38.
40. A vaccine comprising the polypeptide of Claim 25 and a pharmaceutically acceptable carrier.
41. The vaccine of Claim 40, wherein the vaccine comprises at least one other *Neisseria meningitidis* antigen.
42. An antibody immunospecific for the polypeptide or immunogenic fragment of Claim 25.
43. A method for inducing an immune response in a mammal comprising administration of the polypeptide of Claim 25.
44. A method of diagnosing a *Neisseria meningitidis* infection, comprising identifying a polypeptide of Claim 25, or an antibody that is immunospecific for the polypeptide, present within a biological sample from an animal suspected of having such an infection.
45. A method for inducing an immune response in a mammal comprising administration of the isolated polynucleotide of Claim 26.

46. A therapeutic composition useful in treating humans with *Neisseria meningitidis* comprising at least one antibody directed against the polypeptide of claim 25 and a suitable pharmaceutical carrier.

REMARKS

Claims

Claims 1-24 have been canceled without prejudice or disclaimer of the subject matter therein. Applicant reserves the right to prosecute, in one or more patent applications, the canceled claims, the claims as originally filed, and any other claims supported by the specification.

New claims 25-46 have been introduced. No new matter is added.

Support

Support for the new claims is either obvious, or is as described in the text below. Support for compositions of the isolated polypeptide which include an adjuvant recited in the claims may be found, for example, at page 68, lines 25-26. Support for the hybridization conditions may be found, for example, at page 16, line 28 through page 17, line 4. Support for the recitation of sequence relatedness such as in claim 37 may be found in the specification, for example, at page 72, line 7 through page 73, line 2.

Closing Remarks

Allowance of the pending claims is respectfully requested.

Respectfully submitted,



Eric A. Meade
Registration No. 42,876
for
Allen Bloom
Registration No. 29,135
Attorney for Applicant

DECHERT PRICE & RHOADS
Princeton Pike Corporate Center
PO Box 5218
Princeton, New Jersey 08543-5218
Allen Bloom (609) 620-3214
Eric A. Meade (609) 620-3248
Fax: (609) 620-3259
Attn: Allen Bloom, Esq.
(609) 620-3214

Novel Compounds**FIELD OF THE INVENTION**

This invention relates to polynucleotides, (herein referred to as "BASB047

5 polynucleotide(s)", "BASB054 polynucleotide(s)", "BASB068 polynucleotide(s)" and "BASB069 polynucleotide(s)"), polypeptides encoded by them (referred to herein as "BASB047", "BASB054", "BASB068" and "BASB069" respectively or "BASB047 polypeptide(s)", "BASB054 polypeptide(s)", "BASB068 polypeptide(s)" and "BASB069 polypeptide(s)" respectively), recombinant materials and methods for their production. In
10 another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including vaccines against bacterial infections. In a further aspect, the invention relates to diagnostic assays for detecting infection of certain pathogens.

BACKGROUND OF THE INVENTION

15 *Neisseria meningitidis* (meningococcus) is a Gram-negative bacterium frequently isolated from the human upper respiratory tract. It occasionally causes invasive bacterial diseases such as bacteremia and meningitis. The incidence of meningococcal disease shows geographical seasonal and annual differences (Schwartz, B., Moore, P.S., Broome, C.V.; Clin. Microbiol. Rev. 2 (Supplement), S18-S24, 1989). Most disease in temperate countries
20 is due to strains of serogroup B and varies in incidence from 1-10/100,000/year total population sometimes reaching higher values (Kaczmarek, E.B. (1997), Commun. Dis. Rep. Rev. 7: R55-9, 1995; Scholten, R.J.P.M., Bijlmer, H.A., Poolman, J.T. et al. Clin. Infect. Dis. 16: 237-246, 1993; Cruz, C., Pavez, G., Aguilar, E., et al. Epidemiol. Infect. 105: 119-126, 1990).

25 Epidemics dominated by serogroup A meningococci, mostly in central Africa, are encountered, sometimes reaching levels up to 1000/100,000/year (Schwartz, B., Moore, P.S., Broome, C.V. Clin. Microbiol. Rev. 2 (Supplement), S18-S24, 1989). Nearly all cases as a whole of meningococcal disease are caused by serogroup A, B, C, W-135 and Y

meningococci and a tetravalent A, C, W-135, Y polysaccharide vaccine is available (Armand, J., Arminjon, F., Mynard, M.C., Lafaix, C., J. Biol. Stand. 10: 335-339, 1982).

5 The polysaccharide vaccines are currently being improved by way of chemical conjugating them to carrier proteins (Lieberman, J.M., Chiu, S.S., Wong, V.K., et al. JAMA 275 : 1499-1503, 1996).

A serogroup B vaccine is not available, since the B capsular polysaccharide was found to be nonimmunogenic, most likely because it shares structural similarity to host components
10 (Wyle, F.A., Artenstein, M.S., Brandt, M.L. et al. J. Infect. Dis. 126: 514-522, 1972; Finne, J.M., Leinonen, M., Mäkelä, P.M. Lancet ii.: 355-357, 1983).

For many years efforts have been initiated and carried out to develop meningococcal outer membrane based vaccines (de Moraes, J.C., Perkins, B., Camargo, M.C. et al. Lancet 340:
15 1074-1078, 1992; Bjune, G., Hoiby, E.A. Gronnesby, J.K. et al. 338: 1093-1096, 1991). Such vaccines have demonstrated efficacies from 57% - 85% in older children (>4 years) and adolescents.

Many bacterial outer membrane components are present in these vaccines, such as PorA,
20 PorB, Rmp, Opc, Opa, FrpB and the contribution of these components to the observed protection still needs further definition. Other bacterial outer membrane components have been defined by using animal or human antibodies to be potentially relevant to the induction of protective immunity, such as TbpB and NspA (Martin, D., Cadieux, N., Hamel, J., Brodeux, B.R., J. Exp. Med. 185: 1173-1183, 1997; Lissolo, L., Maître-Wilmotte, C.,
25 Dumas, p. et al., Inf. Immun. 63: 884-890, 1995). The mechanisms of protective immunity will involve antibody mediated bactericidal activity and opsonophagocytosis.

A bacteremia animal model has been used to combine all antibody mediated mechanisms (Saukkonen, K., Leinonen, M., Abdillahi, H. Poolman. J. T. Vaccine 7: 325-328, 1989). It is

generally accepted that the late complement component mediated bactericidal mechanism is crucial for immunity against meningococcal disease (Ross, S.C., Rosenthal P.J., Berberic, H.M., Densen, P. J. Infect. Dis. 155: 1266-1275, 1987).

- 5 The frequency of *Neisseria meningitidis* infections has risen dramatically in the past few decades. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate *Neisseria meningitidis* strains that are resistant to some or all of the standard antibiotics. This phenomenon has created an unmet medical need and demand for
- 10 new anti-microbial agents, vaccines, drug screening methods, and diagnostic tests for this organism.

SUMMARY OF THE INVENTION

- 15 The present invention relates to BASB047, BASB054, BASB068 and BASB069, in particular BASB047, BASB054, BASB068 and BASB069 polypeptides and BASB047, BASB054, BASB068 and BASB069 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including prevention and treatment of microbial
- 20 diseases, amongst others. In a further aspect, the invention relates to diagnostic assays for detecting diseases associated with microbial infections and conditions associated with such infections, such as assays for detecting expression or activity of BASB047, BASB054, BASB068 and BASB069 polynucleotides or polypeptides.
- 25 Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.

DESCRIPTION OF THE INVENTION

The invention relates to BASB047, BASB054, BASB068 and BASB069 polypeptides and polynucleotides as described in greater detail below. The invention relates especially to BASB047, BASB054, BASB068 and BASB069 having the nucleotide and amino acid sequences set out in SEQ ID NO:1,3,5,7 and SEQ ID NO:2,4,6,8 respectively. It is understood that sequences recited in the Sequence Listing below as "DNA" represent an exemplification of one embodiment of the invention, since those of ordinary skill will recognize that such sequences can be usefully employed in polynucleotides in general, including ribopolynucleotides.

10

Polypeptides

In one aspect of the invention there are provided polypeptides of *Neisseria meningitidis* referred to herein as "BASB047", "BASB054", "BASB068" and "BASB069", and "BASB047 polypeptides", "BASB054 polypeptides", "BASB068 polypeptides" and "BASB069 polypeptides" as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.

The present invention further provides for:

- (a) an isolated polypeptide which comprises an amino acid sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% or exact identity, to that of SEQ ID NO:2.
- (b) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO:1 over the entire length of SEQ ID NO:1.
- (c) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity, to the amino acid sequence of SEQ ID NO:2.

The BASB043 polypeptide provided in SEQ ID NO:2 is the BASB047 polypeptide from *Neisseria meningitidis* strain ATCC13090.

- 5 The invention also provides an immunogenic fragment of a BASB047 polypeptide, that is, a contiguous portion of the BASB047 polypeptide which has the same or substantially the same immunogenic activity as the polypeptide comprising the amino acid sequence of SEQ ID NO:2. That is to say, the fragment (if necessary when coupled to a carrier) is capable of raising an immune response which recognises the BASB047 polypeptide.
- 10 Such an immunogenic fragment may include, for example, the BASB047 polypeptide lacking an N-terminal leader sequence, and/or a transmembrane domain and/or a C-terminal anchor domain. In a preferred aspect the immunogenic fragment of BASB047 according to the invention comprises substantially all of the extracellular domain of a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet
- 15 more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:2 over the entire length of SEQ ID NO:2.

The present invention further provides for:

- (a) an isolated polypeptide which comprises an amino acid sequence which has at least
- 20 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% or exact identity, to that of SEQ ID NO:4.
- (b) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to
- 25 SEQ ID NO:3 over the entire length of SEQ ID NO:3.
- (c) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity, to the amino acid sequence of SEQ ID NO:4

The BASB054 polypeptide provided in SEQ ID NO:4 is the BASB054 polypeptide from *Neisseria meningitidis* strain ATCC13090.

- 5 The invention also provides an immunogenic fragment of a BASB054 polypeptide, that is, a contiguous portion of the BASB054 polypeptide which has the same or substantially the same immunogenic activity as the polypeptide comprising the amino acid sequence of SEQ ID NO:4. That is to say, the fragment (if necessary when coupled to a carrier) is capable of raising an immune response which recognises the BASB054 polypeptide.
- 10 Such an immunogenic fragment may include, for example, the BASB054 polypeptide lacking an N-terminal leader sequence, and/or a transmembrane domain and/or a C-terminal anchor domain. In a preferred aspect the immunogenic fragment of BASB054 according to the invention comprises substantially all of the extracellular domain of a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet
- 15 more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:4 over the entire length of SEQ ID NO:4.

The present invention further provides for:

- (a) an isolated polypeptide which comprises an amino acid sequence which has at least
- 20 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% or exact identity, to that of SEQ ID NO:6.
- (b) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to
- 25 SEQ ID NO:5 over the entire length of SEQ ID NO:5.
- (c) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity, to the amino acid sequence of SEQ ID NO:6

The BASB068 polypeptide provided in SEQ ID NO:6 is the BASB068 polypeptide from *Neisseria meningitidis* strain ATCC13090.

- 5 The invention also provides an immunogenic fragment of a BASB068 polypeptide, that is, a contiguous portion of the BASB068 polypeptide which has the same or substantially the same immunogenic activity as the polypeptide comprising the amino acid sequence of SEQ ID NO:6. That is to say, the fragment (if necessary when coupled to a carrier) is capable of raising an immune response which recognises the BASB068 polypeptide.
- 10 Such an immunogenic fragment may include, for example, the BASB068 polypeptide lacking an N-terminal leader sequence, and/or a transmembrane domain and/or a C-terminal anchor domain. In a preferred aspect the immunogenic fragment of BASB068 according to the invention comprises substantially all of the extracellular domain of a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet
- 15 more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:6 over the entire length of SEQ ID NO:6.

The present invention further provides for:

- (a) an isolated polypeptide which comprises an amino acid sequence which has at least
- 20 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, most preferably at least 97-99% or exact identity, to that of SEQ ID NO:8.
- (b) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to
- 25 SEQ ID NO:7 over the entire length of SEQ ID NO:7.
- (c) a polypeptide encoded by an isolated polynucleotide comprising a polynucleotide sequence encoding a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity, to the amino acid sequence of SEQ ID NO:8

The BASB069 polypeptide provided in SEQ ID NO:8 is the BASB069 polypeptide from *Neisseria meningitidis* strain ATCC13090.

- 5 The invention also provides an immunogenic fragment of a BASB069 polypeptide, that is, a contiguous portion of the BASB069 polypeptide which has the same or substantially the same immunogenic activity as the polypeptide comprising the amino acid sequence of SEQ ID NO:8. That is to say, the fragment (if necessary when coupled to a carrier) is capable of raising an immune response which recognises the BASB069 polypeptide.
- 10 Such an immunogenic fragment may include, for example, the BASB069 polypeptide lacking an N-terminal leader sequence, and/or a transmembrane domain and/or a C-terminal anchor domain. In a preferred aspect the immunogenic fragment of BASB069 according to the invention comprises substantially all of the extracellular domain of a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet
- 15 more preferably at least 95% identity, most preferably at least 97-99% identity, to that of SEQ ID NO:8 over the entire length of SEQ ID NO:8.

- A fragment is a polypeptide having an amino acid sequence that is entirely the same as part
- 20 but not all of any amino acid sequence of any polypeptide of the invention. As with BASB047, BASB054, BASB068 and BASB069 polypeptides, fragments may be "free-standing", or comprised within a larger polypeptide of which they form a part or region, most preferably as a single continuous region in a single larger polypeptide.

- 25 Preferred fragments include, for example, truncation polypeptides having a portion of an amino acid sequence of SEQ ID NO:2,4,6,8 or of variants thereof, such as a continuous series of residues that includes an amino- and/or carboxyl-terminal amino acid sequence. Degradation forms of the polypeptides of the invention produced by or in a host cell, are also preferred. Further preferred are fragments characterized by structural or functional

attributes such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions.

Further preferred fragments include an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids from the amino acid sequence of SEQ ID NO:2,4,6,8 or an isolated polypeptide comprising an amino acid sequence having at least 15, 20, 30, 40, 50 or 100 contiguous amino acids truncated or deleted from the amino acid sequence of SEQ ID NO:2,4,6,8.

Fragments of the polypeptides of the invention may be employed for producing the corresponding full-length polypeptide by peptide synthesis; therefore, these fragments may be employed as intermediates for producing the full-length polypeptides of the invention.

Particularly preferred are variants in which several, 5-10, 1-5, 1-3, 1-2 or 1 amino acids are substituted, deleted, or added in any combination.

The polypeptides, or immunogenic fragments, of the invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production. Furthermore, addition of exogenous polypeptide or lipid tail or polynucleotide sequences to increase the immunogenic potential of the final molecule is also considered.

In one aspect, the invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa.

Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

The proteins may be chemically conjugated, or expressed as recombinant fusion proteins allowing increased levels to be produced in an expression system as compared to non-fused protein. The fusion partner may assist in providing T helper epitopes (immunological fusion partner), preferably T helper epitopes recognised by humans, or assist in expressing the protein (expression enhancer) at higher yields than the native recombinant protein. Preferably the fusion partner will be both an immunological fusion partner and expression enhancing partner.

Fusion partners include protein D from *Haemophilus influenzae* and the non-structural protein from influenzae virus, NS1 (hemagglutinin). Another fusion partner is the protein known as LytA. Preferably the C terminal portion of the molecule is used. LytA is derived from *Streptococcus pneumoniae* which synthesize an N-acetyl-L-alanine amidase, amidase LytA, (coded by the lytA gene {Gene, 43 (1986) page 265-272}) an autolysin that specifically degrades certain bonds in the peptidoglycan backbone. The C-terminal domain of the LytA protein is responsible for the affinity to

the choline or to some choline analogues such as DEAE. This property has been exploited for the development of *E.coli* C-LytA expressing plasmids useful for expression of fusion proteins. Purification of hybrid proteins containing the C-LytA fragment at its amino terminus has been described {Biotechnology: 10, (1992) page 5 795-798}. It is possible to use the repeat portion of the LytA molecule found in the C terminal end starting at residue 178, for example residues 188 - 305.

The present invention also includes variants of the aforementioned polypeptides, that is polypeptides that vary from the referents by conservative amino acid substitutions, 10 whereby a residue is substituted by another with like characteristics. Typical such substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr.

15 Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

20 It is most preferred that a polypeptide of the invention is derived from *Neisseria meningitidis*, however, it may preferably be obtained from other organisms of the same taxonomic genus. A polypeptide of the invention may also be obtained, for example, from organisms of the same taxonomic family or order.

25

Polynucleotides

It is an object of the invention to provide polynucleotides that encode BASB047 polypeptides, particularly polynucleotides that encode the polypeptide herein designated BASB047.

In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding BASB047 polypeptides comprising a sequence set out in SEQ ID NO:1 which includes a full length gene, or a variant thereof.

5

The BASB047 polynucleotide provided in SEQ ID NO:1 is the BASB047 polynucleotide from *Neisseria meningitidis* strains ATCC13090.

As a further aspect of the invention there are provided isolated nucleic acid molecules encoding and/or expressing BASB047 polypeptides and polynucleotides, particularly *Neisseria meningitidis* BASB047 polypeptides and polynucleotides, including, for example, unprocessed RNAs, ribozyme RNAs, mRNAs, cDNAs, genomic DNAs, B- and Z-DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful polynucleotides and polypeptides, and variants thereof, and compositions comprising the same.

10
15

Another aspect of the invention relates to isolated polynucleotides, including at least one full length gene, that encodes a BASB047 polypeptide having a deduced amino acid sequence of SEQ ID NO:2 and polynucleotides closely related thereto and variants thereof.

20

In another particularly preferred embodiment of the invention there is a BASB047 polypeptide from *Neisseria meningitidis* comprising or consisting of an amino acid sequence of SEQ ID NO:2 or a variant thereof.

25 Using the information provided herein, such as a polynucleotide sequence set out in SEQ ID NO:1 a polynucleotide of the invention encoding BASB047 polypeptide may be obtained using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using *Neisseria meningitidis* cells as starting material, followed by obtaining a full length clone. For example, to obtain a polynucleotide

sequence of the invention, such as a polynucleotide sequence given in SEQ ID NO:1 typically a library of clones of chromosomal DNA of *Neisseria meningitidis* in *E.coli* or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stringent hybridization conditions. By sequencing the individual clones thus identified by hybridization with sequencing primers designed from the original polypeptide or polynucleotide sequence it is then possible to extend the polynucleotide sequence in both directions to determine a full length gene sequence. Conveniently, such sequencing is performed, for example, using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., *MOLECULAR CLONING, A LABORATORY MANUAL*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70). Direct genomic DNA sequencing may also be performed to obtain a full length gene sequence. Illustrative of the invention, each polynucleotide set out in SEQ ID NO:1 was discovered in a DNA library derived from *Neisseria meningitidis*.

Moreover, the DNA sequence set out in SEQ ID NO:1 contains an open reading frame encoding a protein having about the number of amino acid residues set forth in SEQ ID NO:2 with a deduced molecular weight that can be calculated using amino acid residue molecular weight values well known to those skilled in the art.

The polynucleotide of SEQ ID NO:1, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 1201 of SEQ ID NO:1, encodes the polypeptide of SEQ ID NO:2.

In a further aspect, the present invention provides for an isolated polynucleotide comprising or consisting of:

- (a) a polynucleotide sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO:1 over the entire length of SEQ ID NO:1; or
- (b) a polynucleotide sequence encoding a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or 100% exact, to the amino acid sequence of SEQ ID NO:2 over the entire length of SEQ ID NO:2.

- A polynucleotide encoding a polypeptide of the present invention, including homologs and orthologs from species other than *Neisseria meningitidis*, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions (for example, using a temperature in the range of 45 – 65°C and an SDS concentration from 0.1 – 1%) with a labeled or detectable probe consisting of or comprising the sequence of SEQ ID NO:1 or a fragment thereof; and isolating a full-length gene and/or genomic clones containing said polynucleotide sequence.

- The invention provides a polynucleotide sequence identical over its entire length to a coding sequence (open reading frame) in SEQ ID NO:1. Also provided by the invention is a coding sequence for a mature polypeptide or a fragment thereof, by itself as well as a coding sequence for a mature polypeptide or a fragment in reading frame with another coding sequence, such as a sequence encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence. The polynucleotide of the invention may also contain at least one non-coding sequence, including for example, but not limited to at least one non-coding 5' and 3' sequence, such as the transcribed but non-translated sequences, termination signals (such as rho-dependent and rho-independent termination signals), ribosome binding sites, Kozak sequences, sequences that stabilize mRNA, introns, and polyadenylation signals. The polynucleotide sequence may also comprise additional coding sequence encoding additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of the invention, the marker

sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, *Proc. Natl. Acad. Sci., USA* 86: 821-824 (1989), or an HA peptide tag (Wilson *et al.*, *Cell* 37: 767 (1984), both of which may be useful in purifying polypeptide sequence fused to them. Polynucleotides of the invention also include, but are
5 not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.

The nucleotide sequence encoding BASB047 polypeptide of SEQ ID NO:2 may be identical to the polypeptide encoding sequence contained in nucleotides 1 to 1200 of SEQ
10 ID NO:1. Alternatively it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:2. The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the *Neisseria*
15 *meningitidis* BASB047 having an amino acid sequence set out in SEQ ID NO:2. The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, polynucleotides interrupted by integrated phage, an integrated insertion sequence, an integrated vector sequence, an integrated transposon sequence, or due to RNA editing or genomic DNA reorganization) together with
20 additional regions, that also may contain coding and/or non-coding sequences.

The invention further relates to variants of the polynucleotides described herein that encode variants of a polypeptide having a deduced amino acid sequence of SEQ ID NO:2. Fragments of polynucleotides of the invention may be used, for example, to synthesize full-
25 length polynucleotides of the invention.

Further particularly preferred embodiments are polynucleotides encoding BASB047 variants, that have the amino acid sequence of BASB047 polypeptide of SEQ ID NO:2 in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted.

modified, deleted and/or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, that do not alter the properties and activities of BASB047 polypeptide.

- 5 Further preferred embodiments of the invention are polynucleotides that are at least 85% identical over their entire length to a polynucleotide encoding BASB047 polypeptide having an amino acid sequence set out in SEQ ID NO:2 and polynucleotides that are complementary to such polynucleotides. In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these
- 10 particularly preferred polynucleotides, those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%, and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.
- 15 Preferred embodiments are polynucleotides encoding polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by a DNA of SEQ ID NO:1.

- In accordance with certain preferred embodiments of this invention there are provided
- 20 polynucleotides that hybridize, particularly under stringent conditions, to BASB047 polynucleotide sequences, such as those polynucleotides in SEQ ID NO:1.

- The invention further relates to polynucleotides that hybridize to the polynucleotide sequences provided herein. In this regard, the invention especially relates to
- 25 polynucleotides that hybridize under stringent conditions to the polynucleotides described herein. As herein used, the terms "stringent conditions" and "stringent hybridization conditions" mean hybridization occurring only if there is at least 95% and preferably at least 97% identity between the sequences. A specific example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x

SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1x SSC at about 65°C. Hybridization and wash conditions are well known and exemplified in Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein. Solution hybridization may also be used with the polynucleotide sequences provided by the invention.

The invention also provides a polynucleotide consisting of or comprising a polynucleotide sequence obtained by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO:1 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:1 or a fragment thereof; and isolating said polynucleotide sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and primers fully described elsewhere herein.

As discussed elsewhere herein regarding polynucleotide assays of the invention, for instance, the polynucleotides of the invention, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding BASB047 and to isolate cDNA and genomic clones of other genes that have a high identity, particularly high sequence identity, to the BASB047 gene. Such probes generally will comprise at least 15 nucleotide residues or base pairs. Preferably, such probes will have at least 30 nucleotide residues or base pairs and may have at least 50 nucleotide residues or base pairs. Particularly preferred probes will have at least 20 nucleotide residues or base pairs and will have less than 30 nucleotide residues or base pairs.

A coding region of a BASB047 gene may be isolated by screening using a DNA sequence provided in SEQ ID NO:1 to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then

used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

093947 94268860

It is an object of the invention to provide polynucleotides that encode BASB054 polypeptides, particularly polynucleotides that encode the polypeptide herein designated BASB054.

- 5 In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding BASB054 polypeptides comprising a sequence set out in SEQ ID NO:3 which includes a full length gene, or a variant thereof.

- The BASB054 polynucleotide provided in SEQ ID NO:3 is the BASB054
10 polynucleotide from *Neisseria meningitidis* strains ATCC13090.

- As a further aspect of the invention there are provided isolated nucleic acid molecules encoding and/or expressing BASB054 polypeptides and polynucleotides, particularly *Neisseria meningitidis* BASB054 polypeptides and polynucleotides, including, for
15 example, unprocessed RNAs, ribozyme RNAs, mRNAs, cDNAs, genomic DNAs, B- and Z-DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful polynucleotides and polypeptides, and variants thereof, and compositions comprising the same.
- 20 Another aspect of the invention relates to isolated polynucleotides, including at least one full length gene, that encodes a BASB054 polypeptide having a deduced amino acid sequence of SEQ ID NO:4 and polynucleotides closely related thereto and variants thereof.

- In another particularly preferred embodiment of the invention there is a BASB054
25 polypeptide from *Neisseria meningitidis* comprising or consisting of an amino acid sequence of SEQ ID NO:4 or a variant thereof.

Using the information provided herein, such as a polynucleotide sequence set out in SEQ ID NO:3 a polynucleotide of the invention encoding BASB054 polypeptide may be obtained

using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using *Neisseria meningitidis* cells as starting material, followed by obtaining a full length clone. For example, to obtain a polynucleotide sequence of the invention, such as a polynucleotide sequence given in SEQ ID NO:3

5 typically a library of clones of chromosomal DNA of *Neisseria meningitidis* in *E.coli* or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stringent hybridization conditions. By sequencing the individual clones thus identified by hybridization with sequencing primers

10 designed from the original polypeptide or polynucleotide sequence it is then possible to extend the polynucleotide sequence in both directions to determine a full length gene sequence. Conveniently, such sequencing is performed, for example, using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., *MOLECULAR CLONING, A*

15 *LABORATORY MANUAL*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70). Direct genomic DNA sequencing may also be performed to obtain a full length gene sequence. Illustrative of the invention, each polynucleotide set out in SEQ ID NO:3 was discovered in a DNA

20 library derived from *Neisseria meningitidis*.

Moreover, the DNA sequence set out in SEQ ID NO:3 contains an open reading frame encoding a protein having about the number of amino acid residues set forth in SEQ ID NO:4 with a deduced molecular weight that can be calculated using amino acid residue

25 molecular weight values well known to those skilled in the art.

The polynucleotide of SEQ ID NO:3, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 2407 of SEQ ID NO:3, encodes the polypeptide of SEQ ID NO:4.

In a further aspect, the present invention provides for an isolated polynucleotide comprising or consisting of:

- (a) a polynucleotide sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO:3 over the entire length of SEQ ID NO:3; or
- (b) a polynucleotide sequence encoding a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or 100% exact, to the amino acid sequence of SEQ ID NO:4 over the entire length of SEQ ID NO:4.

A polynucleotide encoding a polypeptide of the present invention, including homologs and orthologs from species other than *Neisseria meningitidis*, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions (for example, using a temperature in the range of 45 – 65°C and an SDS concentration from 0.1 – 1%) with a labeled or detectable probe consisting of or comprising the sequence of SEQ ID NO:3 or a fragment thereof; and isolating a full-length gene and/or genomic clones containing said polynucleotide sequence.

The invention provides a polynucleotide sequence identical over its entire length to a coding sequence (open reading frame) in SEQ ID NO:3. Also provided by the invention is a coding sequence for a mature polypeptide or a fragment thereof, by itself as well as a coding sequence for a mature polypeptide or a fragment in reading frame with another coding sequence, such as a sequence encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence. The polynucleotide of the invention may also contain at least one non-coding sequence, including for example, but not limited to at least one non-coding 5' and 3' sequence, such as the transcribed but non-translated sequences, termination signals (such as rho-dependent and rho-independent termination signals), ribosome binding sites, Kozak sequences, sequences that stabilize mRNA, introns, and polyadenylation signals.

The polynucleotide sequence may also comprise additional coding sequence encoding additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, *Proc. Natl. Acad. Sci., USA* 86: 821-824 (1989), or an HA peptide tag (Wilson *et al.*, *Cell* 37: 767 (1984), both of which may be useful in purifying polypeptide sequence fused to them. Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.

10

The nucleotide sequence encoding BASB054 polypeptide of SEQ ID NO:4 may be identical to the polypeptide encoding sequence contained in nucleotides 1 to 2406 of SEQ ID NO:3. Alternatively it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:4.

15 The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the *Neisseria meningitidis* BASB054 having an amino acid sequence set out in SEQ ID NO:4. The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, polynucleotides interrupted by integrated phage, an integrated insertion sequence, an integrated vector sequence, an integrated transposon sequence, or due to RNA editing or genomic DNA reorganization) together with additional regions, that also may contain coding and/or non-coding sequences.

20 The invention further relates to variants of the polynucleotides described herein that encode variants of a polypeptide having a deduced amino acid sequence of SEQ ID NO:4. Fragments of polynucleotides of the invention may be used, for example, to synthesize full-length polynucleotides of the invention.

Further particularly preferred embodiments are polynucleotides encoding BASB054 variants, that have the amino acid sequence of BASB054 polypeptide of SEQ ID NO:4 in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, modified, deleted and/or added, in any combination. Especially preferred among these are
5 silent substitutions, additions and deletions, that do not alter the properties and activities of BASB054 polypeptide.

Further preferred embodiments of the invention are polynucleotides that are at least 85% identical over their entire length to a polynucleotide encoding BASB054 polypeptide having
10 an amino acid sequence set out in SEQ ID NO:4 and polynucleotides that are complementary to such polynucleotides. In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%,
15 and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

Preferred embodiments are polynucleotides encoding polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by a DNA of
20 SEQ ID NO:3.

In accordance with certain preferred embodiments of this invention there are provided polynucleotides that hybridize, particularly under stringent conditions, to BASB054 polynucleotide sequences, such as those polynucleotides in SEQ ID NO:3.
25

The invention further relates to polynucleotides that hybridize to the polynucleotide sequences provided herein. In this regard, the invention especially relates to polynucleotides that hybridize under stringent conditions to the polynucleotides described herein. As herein used, the terms "stringent conditions" and "stringent hybridization

conditions" mean hybridization occurring only if there is at least 95% and preferably at least 97% identity between the sequences. A specific example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1x SSC at about 65°C. Hybridization and wash conditions are well known and exemplified in Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein. Solution hybridization may also be used with the polynucleotide sequences provided by the invention.

The invention also provides a polynucleotide consisting of or comprising a polynucleotide sequence obtained by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO:3 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:3 or a fragment thereof; and isolating said polynucleotide sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and primers fully described elsewhere herein.

As discussed elsewhere herein regarding polynucleotide assays of the invention, for instance, the polynucleotides of the invention, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding BASB054 and to isolate cDNA and genomic clones of other genes that have a high identity, particularly high sequence identity, to the BASB054 gene. Such probes generally will comprise at least 15 nucleotide residues or base pairs. Preferably, such probes will have at least 30 nucleotide residues or base pairs and may have at least 50 nucleotide residues or base pairs. Particularly preferred probes will have at least 20 nucleotide residues or base pairs and will have less than 30 nucleotide residues or base pairs.

- A coding region of a BASB054 gene may be isolated by screening using a DNA sequence provided in SEQ ID NO:3 to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of
- 5 the library the probe hybridizes to.

It is an object of the invention to provide polynucleotides that encode BASB068 polypeptides, particularly polynucleotides that encode the polypeptide herein designated BASB068.

- 5 In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding BASB068 polypeptides comprising a sequence set out in SEQ ID NO:5 which includes a full length gene, or a variant thereof.

- The BASB068 polynucleotide provided in SEQ ID NO:5 is the BASB068
10 polynucleotide from *Neisseria meningitidis* strains ATCC13090.

- As a further aspect of the invention there are provided isolated nucleic acid molecules encoding and/or expressing BASB068 polypeptides and polynucleotides, particularly *Neisseria meningitidis* BASB068 polypeptides and polynucleotides, including, for
15 example, unprocessed RNAs, ribozyme RNAs, mRNAs, cDNAs, genomic DNAs, B- and Z-DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful polynucleotides and polypeptides, and variants thereof, and compositions comprising the same.

- 20 Another aspect of the invention relates to isolated polynucleotides, including at least one full length gene, that encodes a BASB068 polypeptide having a deduced amino acid sequence of SEQ ID NO:6 and polynucleotides closely related thereto and variants thereof.

- In another particularly preferred embodiment of the invention there is a BASB068
25 polypeptide from *Neisseria meningitidis* comprising or consisting of an amino acid sequence of SEQ ID NO:6 or a variant thereof.

Using the information provided herein, such as a polynucleotide sequence set out in SEQ ID NO:5 a polynucleotide of the invention encoding BASB068 polypeptide may be obtained

using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using *Neisseria meningitidis* cells as starting material, followed by obtaining a full length clone. For example, to obtain a polynucleotide sequence of the invention, such as a polynucleotide sequence given in SEQ ID NO:5

5 typically a library of clones of chromosomal DNA of *Neisseria meningitidis* in *E.coli* or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stringent hybridization conditions. By sequencing the individual clones thus identified by hybridization with sequencing primers

10 designed from the original polypeptide or polynucleotide sequence it is then possible to extend the polynucleotide sequence in both directions to determine a full length gene sequence. Conveniently, such sequencing is performed, for example, using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., *MOLECULAR CLONING, A*

15 *LABORATORY MANUAL*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70). Direct genomic DNA sequencing may also be performed to obtain a full length gene sequence. Illustrative of the invention, each polynucleotide set out in SEQ ID NO:5 was discovered in a DNA

20 library derived from *Neisseria meningitidis*.

Moreover, the DNA sequence set out in SEQ ID NO:5 contains an open reading frame encoding a protein having about the number of amino acid residues set forth in SEQ ID NO:6 with a deduced molecular weight that can be calculated using amino acid residue

25 molecular weight values well known to those skilled in the art.

The polynucleotide of SEQ ID NO:5, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 2014 of SEQ ID NO:5, encodes the polypeptide of SEQ ID NO:6.

In a further aspect, the present invention provides for an isolated polynucleotide comprising or consisting of:

- (a) a polynucleotide sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO:5 over the entire length of SEQ ID NO:5; or
- (b) a polynucleotide sequence encoding a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or 100% exact, to the amino acid sequence of SEQ ID NO:6 over the entire length of SEQ ID NO:6.

A polynucleotide encoding a polypeptide of the present invention, including homologs and orthologs from species other than *Neisseria meningitidis*, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions (for example, using a temperature in the range of 45 – 65°C and an SDS concentration from 0.1 – 1%) with a labeled or detectable probe consisting of or comprising the sequence of SEQ ID NO:5 or a fragment thereof; and isolating a full-length gene and/or genomic clones containing said polynucleotide sequence.

The invention provides a polynucleotide sequence identical over its entire length to a coding sequence (open reading frame) in SEQ ID NO:5. Also provided by the invention is a coding sequence for a mature polypeptide or a fragment thereof, by itself as well as a coding sequence for a mature polypeptide or a fragment in reading frame with another coding sequence, such as a sequence encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence. The polynucleotide of the invention may also contain at least one non-coding sequence, including for example, but not limited to at least one non-coding 5' and 3' sequence, such as the transcribed but non-translated sequences, termination signals (such as rho-dependent and rho-independent termination signals), ribosome binding sites, Kozak sequences, sequences that stabilize mRNA, introns, and polyadenylation signals.

- The polynucleotide sequence may also comprise additional coding sequence encoding additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and
- 5 described in Gentz *et al.*, *Proc. Natl. Acad. Sci., USA* 86: 821-824 (1989), or an HA peptide tag (Wilson *et al.*, *Cell* 37: 767 (1984), both of which may be useful in purifying polypeptide sequence fused to them. Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.
- 10 The nucleotide sequence encoding BASB068 polypeptide of SEQ ID NO:6 may be identical to the polypeptide encoding sequence contained in nucleotides 1 to 2013 of SEQ ID NO:5. Alternatively it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:6.
- 15 The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the *Neisseria meningitidis* BASB068 having an amino acid sequence set out in SEQ ID NO:6. The term also encompasses polynucleotides that include a single continuous region or discontinuous
- 20 regions encoding the polypeptide (for example, polynucleotides interrupted by integrated phage, an integrated insertion sequence, an integrated vector sequence, an integrated transposon sequence, or due to RNA editing or genomic DNA reorganization) together with additional regions, that also may contain coding and/or non-coding sequences.
- 25 The invention further relates to variants of the polynucleotides described herein that encode variants of a polypeptide having a deduced amino acid sequence of SEQ ID NO:6. Fragments of polynucleotides of the invention may be used, for example, to synthesize full-length polynucleotides of the invention.

Further particularly preferred embodiments are polynucleotides encoding BASB068 variants, that have the amino acid sequence of BASB068 polypeptide of SEQ ID NO:6 in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, modified, deleted and/or added, in any combination. Especially preferred among these are
5 silent substitutions, additions and deletions, that do not alter the properties and activities of BASB068 polypeptide.

Further preferred embodiments of the invention are polynucleotides that are at least 85% identical over their entire length to a polynucleotide encoding BASB068 polypeptide having
10 an amino acid sequence set out in SEQ ID NO:6 and polynucleotides that are complementary to such polynucleotides. In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%,
15 and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

Preferred embodiments are polynucleotides encoding polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by a DNA of
20 SEQ ID NO:5.

In accordance with certain preferred embodiments of this invention there are provided polynucleotides that hybridize, particularly under stringent conditions, to BASB068 polynucleotide sequences, such as those polynucleotides in SEQ ID NO:5.
25

The invention further relates to polynucleotides that hybridize to the polynucleotide sequences provided herein. In this regard, the invention especially relates to polynucleotides that hybridize under stringent conditions to the polynucleotides described herein. As herein used, the terms "stringent conditions" and "stringent hybridization

conditions" mean hybridization occurring only if there is at least 95% and preferably at least 97% identity between the sequences. A specific example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1x SSC at about 65°C. Hybridization and wash conditions are well known and exemplified in Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein. Solution hybridization may also be used with the polynucleotide sequences provided by the invention.

The invention also provides a polynucleotide consisting of or comprising a polynucleotide sequence obtained by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO:5 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:5 or a fragment thereof; and isolating said polynucleotide sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and primers fully described elsewhere herein.

As discussed elsewhere herein regarding polynucleotide assays of the invention, for instance, the polynucleotides of the invention, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding BASB068 and to isolate cDNA and genomic clones of other genes that have a high identity, particularly high sequence identity, to the BASB068 gene. Such probes generally will comprise at least 15 nucleotide residues or base pairs. Preferably, such probes will have at least 30 nucleotide residues or base pairs and may have at least 50 nucleotide residues or base pairs. Particularly preferred probes will have at least 20 nucleotide residues or base pairs and will have less than 30 nucleotide residues or base pairs.

A coding region of a BASB068 gene may be isolated by screening using a DNA sequence provided in SEQ ID NO:5 to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of

5 the library the probe hybridizes to.

It is an object of the invention to provide polynucleotides that encode BASB069 polypeptides, particularly polynucleotides that encode the polypeptide herein designated BASB069.

- 5 In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding BASB069 polypeptides comprising a sequence set out in SEQ ID NO:7 which includes a full length gene, or a variant thereof.

- The BASB069 polynucleotide provided in SEQ ID NO:7 is the BASB069
10 polynucleotide from *Neisseria meningitidis* strains ATCC13090.

- As a further aspect of the invention there are provided isolated nucleic acid molecules encoding and/or expressing BASB069 polypeptides and polynucleotides, particularly *Neisseria meningitidis* BASB069 polypeptides and polynucleotides, including, for
15 example, unprocessed RNAs, ribozyme RNAs, mRNAs, cDNAs, genomic DNAs, B- and Z-DNAs. Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful polynucleotides and polypeptides, and variants thereof, and compositions comprising the same.

- 20 Another aspect of the invention relates to isolated polynucleotides, including at least one full length gene, that encodes a BASB069 polypeptide having a deduced amino acid sequence of SEQ ID NO:8 and polynucleotides closely related thereto and variants thereof.

- In another particularly preferred embodiment of the invention there is a BASB069
25 polypeptide from *Neisseria meningitidis* comprising or consisting of an amino acid sequence of SEQ ID NO:8 or a variant thereof.

Using the information provided herein, such as a polynucleotide sequence set out in SEQ ID NO:7 a polynucleotide of the invention encoding BASB069 polypeptide may be obtained

using standard cloning and screening methods, such as those for cloning and sequencing chromosomal DNA fragments from bacteria using *Neisseria meningitidis* cells as starting material, followed by obtaining a full length clone. For example, to obtain a polynucleotide sequence of the invention, such as a polynucleotide sequence given in SEQ ID NO:7

- 5 typically a library of clones of chromosomal DNA of *Neisseria meningitidis* in *E.coli* or some other suitable host is probed with a radiolabeled oligonucleotide, preferably a 17-mer or longer, derived from a partial sequence. Clones carrying DNA identical to that of the probe can then be distinguished using stringent hybridization conditions. By sequencing the individual clones thus identified by hybridization with sequencing primers
- 10 designed from the original polypeptide or polynucleotide sequence it is then possible to extend the polynucleotide sequence in both directions to determine a full length gene sequence. Conveniently, such sequencing is performed, for example, using denatured double stranded DNA prepared from a plasmid clone. Suitable techniques are described by Maniatis, T., Fritsch, E.F. and Sambrook et al., *MOLECULAR CLONING, A*
- 15 *LABORATORY MANUAL*, 2nd Ed.; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989). (see in particular Screening By Hybridization 1.90 and Sequencing Denatured Double-Stranded DNA Templates 13.70). Direct genomic DNA sequencing may also be performed to obtain a full length gene sequence. Illustrative of the invention, each polynucleotide set out in SEQ ID NO:7 was discovered in a DNA
- 20 library derived from *Neisseria meningitidis*.

- Moreover, the DNA sequence set out in SEQ ID NO:7 contains an open reading frame encoding a protein having about the number of amino acid residues set forth in SEQ ID NO:8 with a deduced molecular weight that can be calculated using amino acid residue
- 25 molecular weight values well known to those skilled in the art.

The polynucleotide of SEQ ID NO:7, between the start codon at nucleotide number 1 and the stop codon which begins at nucleotide number 2074 of SEQ ID NO:7, encodes the polypeptide of SEQ ID NO:8.

In a further aspect, the present invention provides for an isolated polynucleotide comprising or consisting of:

- (a) a polynucleotide sequence which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or exact identity to SEQ ID NO:7 over the entire length of SEQ ID NO:7; or
(b) a polynucleotide sequence encoding a polypeptide which has at least 85% identity, more preferably at least 90% identity, yet more preferably at least 95% identity, even more preferably at least 97-99% or 100% exact, to the amino acid sequence of SEQ ID NO:8 over the entire length of SEQ ID NO:8.

A polynucleotide encoding a polypeptide of the present invention, including homologs and orthologs from species other than *Neisseria meningitidis*, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions (for example, using a temperature in the range of 45 – 65°C and an SDS concentration from 0.1 – 1%) with a labeled or detectable probe consisting of or comprising the sequence of SEQ ID NO:7 or a fragment thereof; and isolating a full-length gene and/or genomic clones containing said polynucleotide sequence.

The invention provides a polynucleotide sequence identical over its entire length to a coding sequence (open reading frame) in SEQ ID NO:7. Also provided by the invention is a coding sequence for a mature polypeptide or a fragment thereof, by itself as well as a coding sequence for a mature polypeptide or a fragment in reading frame with another coding sequence, such as a sequence encoding a leader or secretory sequence, a pre-, or pro- or prepro-protein sequence. The polynucleotide of the invention may also contain at least one non-coding sequence, including for example, but not limited to at least one non-coding 5' and 3' sequence, such as the transcribed but non-translated sequences, termination signals (such as rho-dependent and rho-independent termination signals), ribosome binding sites, Kozak sequences, sequences that stabilize mRNA, introns, and polyadenylation signals.

The polynucleotide sequence may also comprise additional coding sequence encoding additional amino acids. For example, a marker sequence that facilitates purification of the fused polypeptide can be encoded. In certain embodiments of the invention, the marker sequence is a hexa-histidine peptide, as provided in the pQE vector (Qiagen, Inc.) and described in Gentz *et al.*, *Proc. Natl. Acad. Sci., USA* 86: 821-824 (1989), or an HA peptide tag (Wilson *et al.*, *Cell* 37: 767 (1984), both of which may be useful in purifying polypeptide sequence fused to them. Polynucleotides of the invention also include, but are not limited to, polynucleotides comprising a structural gene and its naturally associated sequences that control gene expression.

10

The nucleotide sequence encoding BASB069 polypeptide of SEQ ID NO:8 may be identical to the polypeptide encoding sequence contained in nucleotides 1 to 2073 of SEQ ID NO:7. Alternatively it may be a sequence, which as a result of the redundancy (degeneracy) of the genetic code, also encodes the polypeptide of SEQ ID NO:8.

15

The term "polynucleotide encoding a polypeptide" as used herein encompasses polynucleotides that include a sequence encoding a polypeptide of the invention, particularly a bacterial polypeptide and more particularly a polypeptide of the *Neisseria meningitidis* BASB069 having an amino acid sequence set out in SEQ ID NO:8. The term also encompasses polynucleotides that include a single continuous region or discontinuous regions encoding the polypeptide (for example, polynucleotides interrupted by integrated phage, an integrated insertion sequence, an integrated vector sequence, an integrated transposon sequence, or due to RNA editing or genomic DNA reorganization) together with additional regions, that also may contain coding and/or non-coding sequences.

20

25

The invention further relates to variants of the polynucleotides described herein that encode variants of a polypeptide having a deduced amino acid sequence of SEQ ID NO:8. Fragments of polynucleotides of the invention may be used, for example, to synthesize full-length polynucleotides of the invention.

Further particularly preferred embodiments are polynucleotides encoding BASB069 variants, that have the amino acid sequence of BASB069 polypeptide of SEQ ID NO:8 in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, modified, deleted and/or added, in any combination. Especially preferred among these are
5 silent substitutions, additions and deletions, that do not alter the properties and activities of BASB069 polypeptide.

Further preferred embodiments of the invention are polynucleotides that are at least 85% identical over their entire length to a polynucleotide encoding BASB069 polypeptide having
10 an amino acid sequence set out in SEQ ID NO:8 and polynucleotides that are complementary to such polynucleotides. In this regard, polynucleotides at least 90% identical over their entire length to the same are particularly preferred, and among these particularly preferred polynucleotides, those with at least 95% are especially preferred. Furthermore, those with at least 97% are highly preferred among those with at least 95%,
15 and among these those with at least 98% and at least 99% are particularly highly preferred, with at least 99% being the more preferred.

Preferred embodiments are polynucleotides encoding polypeptides that retain substantially the same biological function or activity as the mature polypeptide encoded by a DNA of
20 SEQ ID NO:7.

In accordance with certain preferred embodiments of this invention there are provided polynucleotides that hybridize, particularly under stringent conditions, to BASB069 polynucleotide sequences, such as those polynucleotides in SEQ ID NO:7.
25

The invention further relates to polynucleotides that hybridize to the polynucleotide sequences provided herein. In this regard, the invention especially relates to polynucleotides that hybridize under stringent conditions to the polynucleotides described herein. As herein used, the terms "stringent conditions" and "stringent hybridization

conditions" mean hybridization occurring only if there is at least 95% and preferably at least 97% identity between the sequences. A specific example of stringent hybridization conditions is overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 micrograms/ml of denatured, sheared salmon sperm DNA, followed by washing the hybridization support in 0.1x SSC at about 65°C. Hybridization and wash conditions are well known and exemplified in Sambrook, *et al.*, Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor, N.Y., (1989), particularly Chapter 11 therein. Solution hybridization may also be used with the polynucleotide sequences provided by the invention.

The invention also provides a polynucleotide consisting of or comprising a polynucleotide sequence obtained by screening an appropriate library containing the complete gene for a polynucleotide sequence set forth in SEQ ID NO:7 under stringent hybridization conditions with a probe having the sequence of said polynucleotide sequence set forth in SEQ ID NO:7 or a fragment thereof; and isolating said polynucleotide sequence. Fragments useful for obtaining such a polynucleotide include, for example, probes and primers fully described elsewhere herein.

As discussed elsewhere herein regarding polynucleotide assays of the invention, for instance, the polynucleotides of the invention, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding BASB069 and to isolate cDNA and genomic clones of other genes that have a high identity, particularly high sequence identity, to the BASB069 gene. Such probes generally will comprise at least 15 nucleotide residues or base pairs. Preferably, such probes will have at least 30 nucleotide residues or base pairs and may have at least 50 nucleotide residues or base pairs. Particularly preferred probes will have at least 20 nucleotide residues or base pairs and will have less than 30 nucleotide residues or base pairs.

A coding region of a BASB069 gene may be isolated by screening using a DNA sequence provided in SEQ ID NO:7 to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine which members of the library the probe hybridizes to.

There are several methods available and well known to those skilled in the art to obtain full-length DNAs, or extend short DNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman, *et al.*, *PNAS USA* 85: 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs. In the Marathon™ technology, cDNAs have been prepared from mRNA extracted from a chosen tissue and an 'adaptor' sequence ligated onto each end. Nucleic acid amplification (PCR) is then carried out to amplify the "missing" 5' end of the DNA using a combination of gene specific and adaptor specific oligonucleotide primers. The PCR reaction is then repeated using "nested" primers, that is, primers designed to anneal within the amplified product (typically an adaptor specific primer that anneals further 3' in the adaptor sequence and a gene specific primer that anneals further 5' in the selected gene sequence). The products of this reaction can then be analyzed by DNA sequencing and a full-length DNA constructed either by joining the product directly to the existing DNA to give a complete sequence, or carrying out a separate full-length PCR using the new sequence information for the design of the 5' primer.

The polynucleotides and polypeptides of the invention may be employed, for example, as research reagents and materials for discovery of treatments of and diagnostics for diseases, particularly human diseases, as further discussed herein relating to polynucleotide assays.

The polynucleotides of the invention that are oligonucleotides derived from a sequence of SEQ ID NOS:1 – 8 may be used in the processes herein as described, but preferably for PCR, to determine whether or not the polynucleotides identified herein in whole or in part are transcribed in bacteria in infected tissue. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained.

The invention also provides polynucleotides that encode a polypeptide that is the mature protein plus additional amino or carboxyl-terminal amino acids, or amino acids interior to the mature polypeptide (when the mature form has more than one polypeptide chain, for instance). Such sequences may play a role in processing of a protein from precursor to a mature form, may allow protein transport, may lengthen or shorten protein half-life or may facilitate manipulation of a protein for assay or production, among other things. As generally is the case *in vivo*, the additional amino acids may be processed away from the mature protein by cellular enzymes.

For each and every polynucleotide of the invention there is provided a polynucleotide complementary to it. It is preferred that these complementary polynucleotides are fully complementary to each polynucleotide with which they are complementary.

A precursor protein, having a mature form of the polypeptide fused to one or more prosequences may be an inactive form of the polypeptide. When prosequences are removed such inactive precursors generally are activated. Some or all of the prosequences may be removed before activation. Generally, such precursors are called proproteins.

In addition to the standard A, G, C, T/U representations for nucleotides, the term "N" may also be used in describing certain polynucleotides of the invention. "N" means that any of the four DNA or RNA nucleotides may appear at such a designated position in the DNA or RNA sequence, except it is preferred that N is not a nucleic acid that when taken in

combination with adjacent nucleotide positions, when read in the correct reading frame, would have the effect of generating a premature termination codon in such reading frame.

5 In sum, a polynucleotide of the invention may encode a mature protein, a mature protein plus a leader sequence (which may be referred to as a preprotein), a precursor of a mature protein having one or more prosequences that are not the leader sequences of a preprotein, or a preproprotein, which is a precursor to a proprotein, having a leader sequence and one or more prosequences, which generally are removed during processing steps that produce active and mature forms of the polypeptide.

10

In accordance with an aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization.

15 The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscles (Wolff *et al.*, *Hum Mol Genet* (1992) 1: 363, Manthorpe *et al.*, *Hum. Gene Ther.* (1983) 4: 419), delivery of DNA complexed with specific protein carriers (Wu *et al.*, *J Biol Chem.* (1989) 264: 16985), coprecipitation of DNA with calcium phosphate (Benvenisty & Reshef, *PNAS USA*, (1986) 83: 9551), encapsulation of DNA in various forms of liposomes (Kaneda *et al.*, *Science* (1989) 243: 375), particle bombardment (Tang *et al.*, *Nature* (1992) 356:152, Eisenbraun *et al.*, *DNA Cell Biol* (1993) 12: 791) and *in vivo* infection using cloned retroviral vectors (Seeger *et al.*, *PNAS USA* (1984) 81: 5849).

25 **Vectors, Host Cells, Expression Systems**

The invention also relates to vectors that comprise a polynucleotide or polynucleotides of the invention, host cells that are genetically engineered with vectors of the invention and the production of polypeptides of the invention by recombinant techniques. Cell-free

translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the invention.

5 Recombinant polypeptides of the present invention may be prepared by processes well known in those skilled in the art from genetically engineered host cells comprising expression systems. Accordingly, in a further aspect, the present invention relates to expression systems that comprise a polynucleotide or polynucleotides of the present invention, to host cells which are genetically engineered with such expression systems, and to the production of polypeptides of the invention by recombinant techniques.

10

For recombinant production of the polypeptides of the invention, host cells can be genetically engineered to incorporate expression systems or portions thereof or polynucleotides of the invention. Introduction of a polynucleotide into the host cell can be effected by methods described in many standard laboratory manuals, such as Davis, *et al.*,

15

BASIC METHODS IN MOLECULAR BIOLOGY, (1986) and Sambrook, *et al.*, *MOLECULAR CLONING: A LABORATORY MANUAL*, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989), such as, calcium phosphate transfection, DEAE-dextran mediated transfection, transvection, microinjection, cationic lipid-mediated transfection, electroporation, transduction, scrape loading, ballistic

20

introduction and infection.

Representative examples of appropriate hosts include bacterial cells, such as cells of streptococci, staphylococci, enterococci, *E. coli*, streptomyces, cyanobacteria, *Bacillus subtilis*, *Moraxella catarrhalis*, *Haemophilus influenzae* and *Neisseria meningitidis*; fungal cells, such as cells of a yeast, *Kluveromyces*, *Saccharomyces*, a basidiomycete, *Candida albicans* and *Aspergillus*; insect cells such as cells of *Drosophila* S2 and *Spodoptera* Sf9; animal cells such as CHO, COS, HeLa, C127, 3T3, BHK, 293, CV-1 and Bowes melanoma cells; and plant cells, such as cells of a gymnosperm or angiosperm.

25

09889745 " 1.3.10
" 0.0.0.0 " 0.0.0.0
A great variety of expression systems can be used to produce the polypeptides of the invention. Such vectors include, among others, chromosomal-, episomal- and virus-derived vectors, for example, vectors derived from bacterial plasmids, from bacteriophage, from transposons, from yeast episomes, from insertion elements, from yeast chromosomal
5 elements, from viruses such as baculoviruses, papova viruses, such as SV40, vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses, picornaviruses, retroviruses, and alphaviruses and vectors derived from combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, such as cosmids and phagemids. The expression system constructs may contain control regions that regulate as well as engender
10 expression. Generally, any system or vector suitable to maintain, propagate or express polynucleotides and/or to express a polypeptide in a host may be used for expression in this regard. The appropriate DNA sequence may be inserted into the expression system by any of a variety of well-known and routine techniques, such as, for example, those set forth in Sambrook *et al.*, *MOLECULAR CLONING, A LABORATORY MANUAL*, (*supra*).

15 In recombinant expression systems in eukaryotes, for secretion of a translated protein into the lumen of the endoplasmic reticulum, into the periplasmic space or into the extracellular environment, appropriate secretion signals may be incorporated into the expressed polypeptide. These signals may be endogenous to the polypeptide or they may be
20 heterologous signals.

Polypeptides of the present invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose
25 chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most preferably, ion metal affinity chromatography (IMAC) is employed for purification. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis, isolation and or purification.

0989746 1234567890

The expression system may also be a recombinant live microorganism, such as a virus or bacterium. The gene of interest can be inserted into the genome of a live recombinant virus or bacterium. Inoculation and *in vivo* infection with this live vector will lead to *in vivo* expression of the antigen and induction of immune responses. Viruses and bacteria used for this purpose are for instance: poxviruses (e.g; vaccinia, fowlpox, canarypox), alphaviruses (Sindbis virus, Semliki Forest Virus, Venezuelan Equine Encephalitis Virus), adenoviruses, adeno-associated virus, picornaviruses (poliovirus, rhinovirus), herpesviruses (varicella zoster virus, etc), *Listeria*, *Salmonella*, *Shigella*, *Neisseria*, BCG. These viruses and bacteria can be virulent, or attenuated in various ways in order to obtain live vaccines. Such live vaccines also form part of the invention.

Diagnostic, Prognostic, Serotyping and Mutation Assays

- 15 This invention is also related to the use of BASB047, BASB054, BASB068 or BASB069 polynucleotides and polypeptides of the invention for use as diagnostic reagents. Detection of BASB047, BASB054, BASB068 or BASB069 polynucleotides and/or polypeptides in a eukaryote, particularly a mammal, and especially a human, will provide a diagnostic method for diagnosis of disease, staging of disease or response of an infectious organism to drugs.
- 20 Eukaryotes, particularly mammals, and especially humans, particularly those infected or suspected to be infected with an organism comprising the BASB047, BASB054, BASB068 or BASB069 gene or protein, may be detected at the nucleic acid or amino acid level by a variety of well known techniques as well as by methods provided herein.
- 25 Polypeptides and polynucleotides for prognosis, diagnosis or other analysis may be obtained from a putatively infected and/or infected individual's bodily materials. Polynucleotides from any of these sources, particularly DNA or RNA, may be used directly for detection or may be amplified enzymatically by using PCR or any other amplification technique prior to analysis. RNA, particularly mRNA, cDNA and genomic DNA may also be used in the

- same ways. Using amplification, characterization of the species and strain of infectious or resident organism present in an individual, may be made by an analysis of the genotype of a selected polynucleotide of the organism. Deletions and insertions can be detected by a change in size of the amplified product in comparison to a genotype of a reference sequence
- 5 selected from a related organism, preferably a different species of the same genus or a different strain of the same species. Point mutations can be identified by hybridizing amplified DNA to labeled BASB047, BASB054, BASB068 or BASB069 polynucleotide sequences. Perfectly or significantly matched sequences can be distinguished from imperfectly or more significantly mismatched duplexes by DNase or RNase digestion, for
- 10 DNA or RNA respectively, or by detecting differences in melting temperatures or renaturation kinetics. Polynucleotide sequence differences may also be detected by alterations in the electrophoretic mobility of polynucleotide fragments in gels as compared to a reference sequence. This may be carried out with or without denaturing agents. Polynucleotide differences may also be detected by direct DNA or RNA sequencing. See,
- 15 for example, Myers *et al.*, *Science*, 230: 1242 (1985). Sequence changes at specific locations also may be revealed by nuclease protection assays, such as RNase, V1 and S1 protection assay or a chemical cleavage method. See, for example, Cotton *et al.*, *Proc. Natl. Acad. Sci., USA*, 85: 4397-4401 (1985).
- 20 In another embodiment, an array of oligonucleotides probes comprising a BASB047, BASB054, BASB068 or BASB069 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of, for example, genetic mutations, serotype, taxonomic classification or identification. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular
- 25 genetics including gene expression, genetic linkage, and genetic variability (see, for example, Chee *et al.*, *Science*, 274: 610 (1996)).

Thus in another aspect, the present invention relates to a diagnostic kit which comprises:

- (a) a polynucleotide of the present invention, preferably the nucleotide sequence of SEQ ID NO:1,3,5,7 or a fragment thereof ;
- (b) a nucleotide sequence complementary to that of (a);
- (c) a polypeptide of the present invention, preferably the polypeptide of SEQ ID NO:2,4,6,8 or a fragment thereof; or
- (d) an antibody to a polypeptide of the present invention, preferably to the polypeptide of SEQ ID NO:2,4,6,8.

It will be appreciated that in any such kit, (a), (b), (c) or (d) may comprise a substantial component. Such a kit will be of use in diagnosing a disease or susceptibility to a disease, among others.

This invention also relates to the use of polynucleotides of the present invention as diagnostic reagents. Detection of a mutated form of a polynucleotide of the invention, preferably of SEQ ID NO:1,3,5 or 7 which is associated with a disease or pathogenicity will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, a prognosis of a course of disease, a determination of a stage of disease, or a susceptibility to a disease, which results from under-expression, over-expression or altered expression of the polynucleotide. Organisms, particularly infectious organisms, carrying mutations in such polynucleotide may be detected at the polynucleotide level by a variety of techniques, such as those described elsewhere herein.

Cells from an organism carrying mutations or polymorphisms (allelic variations) in a polynucleotide and/or polypeptide of the invention may also be detected at the polynucleotide or polypeptide level by a variety of techniques, to allow for serotyping, for example. For example, RT-PCR can be used to detect mutations in the RNA. It is particularly preferred to use RT-PCR in conjunction with automated detection systems, such as, for example, GeneScan. RNA, cDNA or genomic DNA may also be used for the same purpose, PCR. As an example, PCR primers complementary to a polynucleotide encoding

BASB047, BASB054, BASB068 or BASB069 polypeptide can be used to identify and analyze mutations.

5 The invention further provides primers with 1, 2, 3 or 4 nucleotides removed from the 5' and/or the 3' end. These primers may be used for, among other things, amplifying BASB047, BASB054, BASB068 or BASB069 DNA and/or RNA isolated from a sample derived from an individual, such as a bodily material. The primers may be used to amplify a polynucleotide isolated from an infected individual, such that the polynucleotide may then be subject to various techniques for elucidation of the polynucleotide sequence. In this way, 10 mutations in the polynucleotide sequence may be detected and used to diagnose and/or prognose the infection or its stage or course, or to serotype and/or classify the infectious agent.

15 The invention further provides a process for diagnosing disease, preferably bacterial infections, more preferably infections caused by *Neisseria meningitidis*, comprising determining from a sample derived from an individual, such as a bodily material, an increased level of expression of polynucleotide having a sequence of SEQ ID NO:1,3,5 or 7. Increased or decreased expression of a BASB047, BASB054, BASB068 or BASB069 polynucleotide can be measured using any one of the methods well known in the art for the 20 quantitation of polynucleotides, such as, for example, amplification, PCR, RT-PCR, RNase protection, Northern blotting, spectrometry and other hybridization methods.

In addition, a diagnostic assay in accordance with the invention for detecting over-expression of BASB047, BASB054, BASB068 or BASB069 polypeptide compared to 25 normal control tissue samples may be used to detect the presence of an infection, for example. Assay techniques that can be used to determine levels of a BASB047, BASB054, BASB068 or BASB069 polypeptide, in a sample derived from a host, such as a bodily material, are well-known to those of skill in the art. Such assay methods include

radioimmunoassays, competitive-binding assays, Western Blot analysis, antibody sandwich assays, antibody detection and ELISA assays.

- The polynucleotides of the invention may be used as components of polynucleotide arrays, preferably high density arrays or grids. These high density arrays are particularly useful for diagnostic and prognostic purposes. For example, a set of spots each comprising a different gene, and further comprising a polynucleotide or polynucleotides of the invention, may be used for probing, such as using hybridization or nucleic acid amplification, using a probe obtained or derived from a bodily sample, to determine the presence of a particular polynucleotide sequence or related sequence in an individual. Such a presence may indicate the presence of a pathogen, particularly *Neisseria meningitidis*, and may be useful in diagnosing and/or prognosing disease or a course of disease. A grid comprising a number of variants of the polynucleotide sequence of SEQ ID NO:1,3,5,7 are preferred. Also preferred is a grid comprising a number of variants of a polynucleotide sequence encoding the polypeptide sequence of SEQ ID NO:2,4,6 or 8.

Antibodies

- The polypeptides and polynucleotides of the invention or variants thereof, or cells expressing the same can be used as immunogens to produce antibodies immunospecific for such polypeptides or polynucleotides respectively.

- In certain preferred embodiments of the invention there are provided antibodies against BASB047, BASB054, BASB068 or BASB069 polypeptides or polynucleotides.

Antibodies generated against the polypeptides or polynucleotides of the invention can be obtained by administering the polypeptides and/or polynucleotides of the invention, or epitope-bearing fragments of either or both, analogues of either or both, or cells expressing

either or both, to an animal, preferably a nonhuman, using routine protocols. For preparation of monoclonal antibodies, any technique known in the art that provides antibodies produced by continuous cell line cultures can be used. Examples include various techniques, such as those in Kohler, G. and Milstein, C., *Nature* 256: 495-497 (1975);

- 5 Kozbor *et al.*, *Immunology Today* 4: 72 (1983); Cole *et al.*, pg. 77-96 in *MONOCLONAL ANTIBODIES AND CANCER THERAPY*, Alan R. Liss, Inc. (1985).

- Techniques for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to polypeptides or polynucleotides of this
10 invention. Also, transgenic mice, or other organisms or animals, such as other mammals, may be used to express humanized antibodies immunospecific to the polypeptides or polynucleotides of the invention.

- Alternatively, phage display technology may be utilized to select antibody genes with
15 binding activities towards a polypeptide of the invention either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing anti- BASB047, BASB054, BASB068 or BASB069 or from naive libraries (McCafferty, *et al.*, (1990), *Nature* 348, 552-554; Marks, *et al.*, (1992) *Biotechnology* 10, 779-783). The affinity of these antibodies can also be improved by, for example, chain shuffling (Clackson *et al.*,
20 (1991) *Nature* 352: 628).

- The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptides or polynucleotides of the invention to purify the polypeptides or polynucleotides by, for example, affinity chromatography.

- 25 Thus, among others, antibodies against BASB047, BASB054, BASB068 or BASB069 - polypeptide or BASB047, BASB054, BASB068 or BASB069 -polynucleotide may be employed to treat infections, particularly bacterial infections.

Polypeptide variants include antigenically, epitopically or immunologically equivalent variants form a particular aspect of this invention.

Preferably, the antibody or variant thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized," where the complementarity determining region or regions of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody, for example as described in Jones *et al.* (1986), *Nature* 321, 522-525 or Tempest *et al.*, (1991) *Biotechnology* 9, 266-273.

Antagonists and Agonists - Assays and Molecules

Polypeptides and polynucleotides of the invention may also be used to assess the binding of small molecule substrates and ligands in, for example, cells, cell-free preparations, chemical libraries, and natural product mixtures. These substrates and ligands may be natural substrates and ligands or may be structural or functional mimetics. See, *e.g.*, Coligan *et al.*, *Current Protocols in Immunology* 1(2): Chapter 5 (1991).

The screening methods may simply measure the binding of a candidate compound to the polypeptide or polynucleotide, or to cells or membranes bearing the polypeptide or polynucleotide, or a fusion protein of the polypeptide by means of a label directly or indirectly associated with the candidate compound. Alternatively, the screening method may involve competition with a labeled competitor. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide or polynucleotide, using detection systems appropriate to the cells comprising the polypeptide or polynucleotide. Inhibitors of activation are generally assayed in the presence of a known agonist and the effect on activation by the agonist by the presence of the candidate compound is observed. Constitutively active polypeptide and/or constitutively expressed polypeptides and polynucleotides may be employed in

screening methods for inverse agonists or inhibitors, in the absence of an agonist or inhibitor, by testing whether the candidate compound results in inhibition of activation of the polypeptide or polynucleotide, as the case may be. Further, the screening methods may simply comprise the steps of mixing a candidate compound with a solution
5 containing a polypeptide or polynucleotide of the present invention, to form a mixture, measuring BASB047, BASB054, BASB068 or BASB069 polypeptide and/or polynucleotide activity in the mixture, and comparing the BASB047, BASB054, BASB068 or BASB069 polypeptide and/or polynucleotide activity of the mixture to a standard. Fusion proteins, such as those made from Fc portion and BASB047, BASB054,
10 BASB068 or BASB069 polypeptide, as hereinbefore described, can also be used for high-throughput screening assays to identify antagonists of the polypeptide of the present invention, as well as of phylogenetically and and/or functionally related polypeptides (see D. Bennett *et al.*, J Mol Recognition, 8:52-58 (1995); and K. Johanson *et al.*, J Biol Chem, 270(16):9459-9471 (1995)).

15 The polynucleotides, polypeptides and antibodies that bind to and/or interact with a polypeptide of the present invention may also be used to configure screening methods for detecting the effect of added compounds on the production of mRNA and/or polypeptide in cells. For example, an ELISA assay may be constructed for measuring secreted or cell
20 associated levels of polypeptide using monoclonal and polyclonal antibodies by standard methods known in the art. This can be used to discover agents which may inhibit or enhance the production of polypeptide (also called antagonist or agonist, respectively) from suitably manipulated cells or tissues.

25 The invention also provides a method of screening compounds to identify those which enhance (agonist) or block (antagonist) the action of BASB047, BASB054, BASB068 or BASB069 polypeptides or polynucleotides, particularly those compounds that are bacteristatic and/or bactericidal. The method of screening may involve high-throughput techniques. For example, to screen for agonists or antagonists, a synthetic reaction mix. a

cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, comprising BASB047, BASB054, BASB068 or BASB069 polypeptide and a labeled substrate or ligand of such polypeptide is incubated in the absence or the presence of a candidate molecule that may be a BASB047, BASB054, BASB068 or BASB069 agonist or antagonist. The ability of the candidate molecule to agonize or antagonize the BASB047, BASB054, BASB068 or BASB069 polypeptide is reflected in decreased binding of the labeled ligand or decreased production of product from such substrate. Molecules that bind gratuitously, *i.e.*, without inducing the effects of BASB047, BASB054, BASB068 or BASB069 polypeptide are most likely to be good antagonists. Molecules that bind well and, as the case may be, increase the rate of product production from substrate, increase signal transduction, or increase chemical channel activity are agonists. Detection of the rate or level of, as the case may be, production of product from substrate, signal transduction, or chemical channel activity may be enhanced by using a reporter system. Reporter systems that may be useful in this regard include but are not limited to colorimetric, labeled substrate converted into product, a reporter gene that is responsive to changes in BASB047, BASB054, BASB068 or BASB069 polynucleotide or polypeptide activity, and binding assays known in the art.

Another example of an assay for BASB047, BASB054, BASB068 or BASB069 agonists is a competitive assay that combines BASB047, BASB054, BASB068 or BASB069 and a potential agonist with BASB047, BASB054, BASB068 or BASB069 -binding molecules, recombinant BASB047, BASB054, BASB068 or BASB069 binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. BASB047, BASB054, BASB068 or BASB069 can be labeled, such as by radioactivity or a colorimetric compound, such that the number of BASB047, BASB054, BASB068 or BASB069 molecules bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include, among others, small organic molecules, peptides, polypeptides and antibodies that bind to a polynucleotide and/or polypeptide of the invention and thereby inhibit or extinguish its activity or expression. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds the same sites on a binding molecule, such as a binding molecule, without inducing BASB047, BASB054, BASB068 or BASB069 -induced activities, thereby preventing the action or expression of BASB047, BASB054, BASB068 or BASB069 polypeptides and/or polynucleotides by excluding BASB047, BASB054, BASB068 or BASB069 polypeptides and/or polynucleotides from binding.

10

Potential antagonists include a small molecule that binds to and occupies the binding site of the polypeptide thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules. Other potential antagonists include antisense molecules (see Okano, *J. Neurochem.* 56: 560 (1991); *OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION*, CRC Press, Boca Raton, FL (1988), for a description of these molecules). Preferred potential antagonists include compounds related to and variants of BASB047, BASB054, BASB068 or BASB069.

20

In a further aspect, the present invention relates to genetically engineered soluble fusion proteins comprising a polypeptide of the present invention, or a fragment thereof, and various portions of the constant regions of heavy or light chains of immunoglobulins of various subclasses (IgG, IgM, IgA, IgE). Preferred as an immunoglobulin is the constant part of the heavy chain of human IgG, particularly IgG1, where fusion takes place at the hinge region. In a particular embodiment, the Fc part can be removed simply by incorporation of a cleavage sequence which can be cleaved with blood clotting factor Xa. Furthermore, this invention relates to processes for the preparation of these fusion proteins by genetic engineering, and to the use thereof for drug screening, diagnosis and

25

therapy. A further aspect of the invention also relates to polynucleotides encoding such fusion proteins. Examples of fusion protein technology can be found in International Patent Application Nos. WO94/29458 and WO94/22914.

- 5 Each of the polynucleotide sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein, upon expression, can be used as a target for the screening of antibacterial drugs. Additionally, the polynucleotide sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to
10 construct antisense sequences to control the expression of the coding sequence of interest.

- The invention also provides the use of the polypeptide, polynucleotide, agonist or antagonist of the invention to interfere with the initial physical interaction between a pathogen or pathogens and a eukaryotic, preferably mammalian, host responsible for
15 sequelae of infection. In particular, the molecules of the invention may be used: in the prevention of adhesion of bacteria, in particular gram positive and/or gram negative bacteria, to eukaryotic, preferably mammalian, extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; to block bacterial adhesion between eukaryotic, preferably mammalian, extracellular matrix proteins and bacterial
20 BASB047, BASB054, BASB068 or BASB069 proteins that mediate tissue damage and/or; to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.

- In accordance with yet another aspect of the invention, there are provided BASB047,
25 BASB054, BASB068 or BASB069 agonists and antagonists, preferably bacteristatic or bactericidal agonists and antagonists.

The antagonists and agonists of the invention may be employed, for instance, to prevent, inhibit and/or treat diseases.

In a further aspect, the present invention relates to mimotopes of the polypeptide of the invention. A mimotope is a peptide sequence, sufficiently similar to the native peptide (sequentially or structurally), which is capable of being recognised by antibodies which
5 recognise the native peptide; or is capable of raising antibodies which recognise the native peptide when coupled to a suitable carrier.

Peptide mimotopes may be designed for a particular purpose by addition, deletion or substitution of elected amino acids. Thus, the peptides may be modified for the purposes
10 of ease of conjugation to a protein carrier. For example, it may be desirable for some chemical conjugation methods to include a terminal cysteine. In addition it may be desirable for peptides conjugated to a protein carrier to include a hydrophobic terminus distal from the conjugated terminus of the peptide, such that the free unconjugated end of the peptide remains associated with the surface of the carrier protein. Thereby
15 presenting the peptide in a conformation which most closely resembles that of the peptide as found in the context of the whole native molecule. For example, the peptides may be altered to have an N-terminal cysteine and a C-terminal hydrophobic amidated tail. Alternatively, the addition or substitution of a D-stereoisomer form of one or more of the amino acids may be performed to create a beneficial derivative, for example to
20 enhance stability of the peptide.

Alternatively, peptide mimotopes may be identified using antibodies which are capable themselves of binding to the polypeptides of the present invention using techniques such as phage display technology (EP 0 552 267 B1). This technique, generates a large number
25 of peptide sequences which mimic the structure of the native peptides and are, therefore, capable of binding to anti-native peptide antibodies, but may not necessarily themselves share significant sequence homology to the native polypeptide.

Vaccines

Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal, preferably humans, which comprises inoculating the individual with BASB047, BASB054, BASB068 or BASB069

- 5 polynucleotide and/or polypeptide, or a fragment or variant thereof, adequate to produce antibody and/ or T cell immune response to protect said individual from infection, particularly bacterial infection and most particularly *Neisseria meningitidis* infection. Also provided are methods whereby such immunological response slows bacterial replication. Yet another aspect of the invention relates to a method of inducing
- 10 immunological response in an individual which comprises delivering to such individual a nucleic acid vector, sequence or ribozyme to direct expression of BASB047, BASB054, BASB068 or BASB069 polynucleotide and/or polypeptide, or a fragment or a variant thereof, for expressing BASB047, BASB054, BASB068 or BASB069 polynucleotide and/or polypeptide, or a fragment or a variant thereof *in vivo* in order to induce an
- 15 immunological response, such as, to produce antibody and/ or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual, preferably a human, from disease, whether that disease is already established within the individual or not. One example of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise. Such nucleic acid vector may
- 20 comprise DNA, RNA, a ribozyme, a modified nucleic acid, a DNA/RNA hybrid, a DNA-protein complex or an RNA-protein complex.

A further aspect of the invention relates to an immunological composition that when introduced into an individual, preferably a human, capable of having induced within it an

25 immunological response, induces an immunological response in such individual to a BASB047, BASB054, BASB068 or BASB069 polynucleotide and/or polypeptide encoded therefrom, wherein the composition comprises a recombinant BASB047, BASB054, BASB068 or BASB069 polynucleotide and/or polypeptide encoded therefrom and/or comprises DNA and/or RNA which encodes and expresses an antigen of said BASB047.

BASB054, BASB068 or BASB069 polynucleotide, polypeptide encoded therefrom, or other polypeptide of the invention. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity and/or cellular immunity, such as cellular immunity arising from CTL or CD4+ T cells.

5

A BASB047, BASB054, BASB068 or BASB069 polypeptide or a fragment thereof may be fused with co-protein or chemical moiety which may or may not by itself produce antibodies, but which is capable of stabilizing the first protein and producing a fused or modified protein which will have antigenic and/or immunogenic properties, and preferably protective properties. Thus fused recombinant protein, preferably further comprises an antigenic co-protein, such as lipoprotein D from *Haemophilus influenzae*, Glutathione-S-transferase (GST) or beta-galactosidase, or any other relatively large co-protein which solubilizes the protein and facilitates production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system of the organism receiving the protein. The co-protein may be attached to either the amino- or carboxy-terminus of the first protein.

10

15

In a vaccine composition according to the invention, a BASB047, BASB054, BASB068 or BASB069 polypeptide and/or polynucleotide, or a fragment, or a mimotope, or a variant thereof may be present in a vector, such as the live recombinant vectors described above for example live bacterial vectors.

20

Also suitable are non-live vectors for the BASB047, BASB054, BASB068 or BASB069 polypeptide, for example bacterial outer-membrane vesicles or "blebs". OM blebs are derived from the outer membrane of the two-layer membrane of Gram-negative bacteria and have been documented in many Gram-negative bacteria (Zhou, L *et al.* 1998. *FEMS Microbiol. Lett.* 163:223-228) including *C. trachomatis* and *C. psittaci*. A non-exhaustive list of bacterial pathogens reported to produce blebs also includes: *Bordetella pertussis*, *Borrelia burgdorferi*, *Brucella melitensis*, *Brucella ovis*, *Escherichia coli*, *Haemophilus*

25

influenza, Legionella pneumophila, Neisseria gonorrhoeae, Neisseria meningitidis, Pseudomonas aeruginosa and Yersinia enterocolitica.

- Blebs have the advantage of providing outer-membrane proteins in their native
- 5 conformation and are thus particularly useful for vaccines. Blebs can also be improved for vaccine use by engineering the bacterium so as to modify the expression of one or more molecules at the outer membrane. Thus for example the expression of a desired immunogenic protein at the outer membrane, such as the BASB047, BASB054, BASB068 or BASB069 polypeptide, can be introduced or upregulated (e.g. by altering the
- 10 promoter). Instead or in addition, the expression of outer-membrane molecules which are either not relevant (e.g. unprotective antigens or immunodominant but variable proteins) or detrimental (e.g. toxic molecules such as LPS, or potential inducers of an autoimmune response) can be downregulated. These approaches are discussed in more detail below.
- 15 The non-coding flanking regions of the BASB047, BASB054, BASB068 or BASB069 gene contain regulatory elements important in the expression of the gene. This regulation takes place both at the transcriptional and translational level. The sequence of these regions, either upstream or downstream of the open reading frame of the gene, can be obtained by DNA sequencing. This sequence information allows the determination of
- 20 potential regulatory motifs such as the different promoter elements, terminator sequences, inducible sequence elements, repressors, elements responsible for phase variation, the shine-dalgarno sequence, regions with potential secondary structure involved in regulation, as well as other types of regulatory motifs or sequences.
- 25 This sequence information allows the modulation of the natural expression of the BASB047, BASB054, BASB068 or BASB069 gene. The upregulation of the gene expression may be accomplished by altering the promoter, the shine-dalgarno sequence, potential repressor or operator elements, or any other elements involved. Likewise, downregulation of expression can be achieved by similar types of modification.

Alternatively, by changing phase variation sequences, the expression of the gene can be put under phase variation control, or it may be uncoupled from this regulation. In another approach, the expression of the gene can be put under the control of one or more inducible elements allowing regulated expression. Examples of such regulation include, but are not
5 limited to, induction by temperature shift, addition of inductor substrates like selected carbohydrates or their derivatives, trace elements, vitamins, co-factors, metal ions, etc.

Such modifications as described above can be introduced by several different means. The modification of sequences involved in gene expression can be carried out *in vivo* by
10 random mutagenesis followed by selection for the desired phenotype. Another approach consists in isolating the region of interest and modifying it by random mutagenesis, or site-directed replacement, insertion or deletion mutagenesis. The modified region can then be reintroduced into the bacterial genome by homologous recombination, and the effect on gene expression can be assessed. In another approach, the sequence knowledge of the
15 region of interest can be used to replace or delete all or part of the natural regulatory sequences. In this case, the regulatory region targeted is isolated and modified so as to contain the regulatory elements from another gene, a combination of regulatory elements from different genes, a synthetic regulatory region, or any other regulatory region, or to delete selected parts of the wild-type regulatory sequences. These modified sequences can
20 then be reintroduced into the bacterium via homologous recombination into the genome. A non-exhaustive list of preferred promoters that could be used for up-regulation of gene expression includes the promoters *porA*, *porB*, *lbpB*, *tbpB*, *p110*, *lst*, *hpuAB* from *N. meningitidis* or *N. gonorrhoeae*; *ompCD*, *copB*, *lbpB*, *ompE*, *UspA1*; *UspA2*; *TbpB* from *M. Catarrhalis*; *p1*, *p2*, *p4*, *p5*, *p6*, *lpD*, *tbpB*, *D15*, *Hia*, *Hmw1*, *Hmw2* from *H.*
25 *influenzae*.

In one example, the expression of the gene can be modulated by exchanging its promoter with a stronger promoter (through isolating the upstream sequence of the gene, *in vitro* modification of this sequence, and reintroduction into the genome by homologous

recombination). Upregulated expression can be obtained in both the bacterium as well as in the outer membrane vesicles shed (or made) from the bacterium.

In other examples, the described approaches can be used to generate recombinant

- 5 bacterial strains with improved characteristics for vaccine applications. These can be, but are not limited to, attenuated strains, strains with increased expression of selected antigens, strains with knock-outs (or decreased expression) of genes interfering with the immune response, strains with modulated expression of immunodominant proteins, strains with modulated shedding of outer-membrane vesicles.

10

- Thus, also provided by the invention is a modified upstream region of the BASB047, BASB054, BASB068 or BASB069 gene, which modified upstream region contains a heterologous regulatory element which alters the expression level of the BASB047, BASB054, BASB068 or BASB069 protein located at the outer membrane. The upstream
- 15 region according to this aspect of the invention includes the sequence upstream of the BASB047, BASB054, BASB068 or BASB069 gene. The upstream region starts immediately upstream of the BASB047, BASB054, BASB068 or BASB069 gene and continues usually to a position no more than about 1000 bp upstream of the gene from the ATG start codon. In the case of a gene located in a polycistronic sequence (operon) the
- 20 upstream region can start immediately preceding the gene of interest, or preceding the first gene in the operon. Preferably, a modified upstream region according to this aspect of the invention contains a heterologous promotor at a position between 500 and 700 bp upstream of the ATG.

- 25 Thus, the invention provides a BASB047, BASB054, BASB068 and BASB069 polypeptide, in a modified bacterial bleb. The invention further provides modified host cells capable of producing the non-live membrane-based bleb vectors. The invention further provides nucleic acid vectors comprising the BASB047, BASB054, BASB068 and

BASB069 gene having a modified upstream region containing a heterologous regulatory element.

Further provided by the invention are processes to prepare the host cells and bacterial blebs
5 according to the invention.

Also provided by this invention are compositions, particularly vaccine compositions, and methods comprising the polypeptides and/or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y. *et al.* Science
10 273: 352 (1996).

Also, provided by this invention are methods using the described polynucleotide or particular fragments thereof, which have been shown to encode non-variable regions of bacterial cell surface proteins, in polynucleotide constructs used in such genetic
15 immunization experiments in animal models of infection with *Neisseria meningitidis*. Such experiments will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. It is believed that this approach will allow for the subsequent preparation of monoclonal antibodies of particular value, derived from the requisite organ of the animal successfully resisting or clearing infection,
20 for the development of prophylactic agents or therapeutic treatments of bacterial infection, particularly *Neisseria meningitidis* infection, in mammals, particularly humans.

The invention also includes a vaccine formulation which comprises an immunogenic recombinant polypeptide and/or polynucleotide of the invention together with a suitable
25 carrier, such as a pharmaceutically acceptable carrier. Since the polypeptides and polynucleotides may be broken down in the stomach, each is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants.

5 buffers, bacteristatic compounds and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.

10 The vaccine formulation of the invention may also include adjuvant systems for enhancing the immunogenicity of the formulation. Preferably the adjuvant system raises preferentially a TH1 type of response.

15 An immune response may be broadly distinguished into two extreme catagories, being a humoral or cell mediated immune responses (traditionally characterised by antibody and cellular effector mechanisms of protection respectively). These categories of response have been termed TH1-type responses (cell-mediated response), and TH2-type immune responses (humoral response).

20 Extreme TH1-type immune responses may be characterised by the generation of antigen specific, haplotype restricted cytotoxic T lymphocytes, and natural killer cell responses. In mice TH1-type responses are often characterised by the generation of antibodies of the IgG2a subtype, whilst in the human these correspond to IgG1 type antibodies. TH2-type immune responses are characterised by the generation of a broad range of immunoglobulin isotypes including in mice IgG1, IgA, and IgM.

25 It can be considered that the driving force behind the development of these two types of immune responses are cytokines. High levels of TH1-type cytokines tend to favour the induction of cell mediated immune responses to the given antigen, whilst high levels of TH2-type cytokines tend to favour the induction of humoral immune responses to the antigen.

5 The distinction of TH1 and TH2-type immune responses is not absolute. In reality an individual will support an immune response which is described as being predominantly TH1 or predominantly TH2. However, it is often convenient to consider the families of cytokines in terms of that described in murine CD4 +ve T cell clones by Mosmann and Coffman (*Mosmann, T.R. and Coffman, R.L. (1989) TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annual Review of Immunology, 7, p145-173*). Traditionally, TH1-type responses are associated with the production of the INF- γ and IL-2 cytokines by T-lymphocytes. Other cytokines
10 often directly associated with the induction of TH1-type immune responses are not produced by T-cells, such as IL-12. In contrast, TH2- type responses are associated with the secretion of IL-4, IL-5, IL-6 and IL-13.

15 It is known that certain vaccine adjuvants are particularly suited to the stimulation of either TH1 or TH2 - type cytokine responses. Traditionally the best indicators of the TH1:TH2 balance of the immune response after a vaccination or infection includes direct measurement of the production of TH1 or TH2 cytokines by T lymphocytes *in vitro* after restimulation with antigen, and/or the measurement of the IgG1:IgG2a ratio of antigen specific antibody responses.

20 Thus, a TH1-type adjuvant is one which preferentially stimulates isolated T-cell populations to produce high levels of TH1-type cytokines when re-stimulated with antigen *in vitro*, and promotes development of both CD8+ cytotoxic T lymphocytes and antigen specific immunoglobulin responses associated with TH1-type isotype.

25 Adjuvants which are capable of preferential stimulation of the TH1 cell response are described in International Patent Application No. WO 94/00153 and WO 95/17209.

3 De-O-acylated monophosphoryl lipid A (3D-MPL) is one such adjuvant. This is known from GB 2220211 (Ribi). Chemically it is a mixture of 3 De-O-acylated monophosphoryl lipid A with 4, 5 or 6 acylated chains and is manufactured by Ribi Immunochem, Montana. A preferred form of 3 De-O-acylated monophosphoryl lipid
5 A is disclosed in European Patent 0 689 454 B1 (SmithKline Beecham Biologicals SA).

Preferably, the particles of 3D-MPL are small enough to be sterile filtered through a 0.22micron membrane (European Patent number 0 689 454).

3D-MPL will be present in the range of 10µg - 100µg preferably 25-50µg per dose
10 wherein the antigen will typically be present in a range 2-50µg per dose.

Another preferred adjuvant comprises QS21, an Hplc purified non-toxic fraction derived from the bark of Quillaja Saponaria Molina. Optionally this may be admixed with 3 De-O-acylated monophosphoryl lipid A (3D-MPL), optionally together with a
15 carrier.

The method of production of QS21 is disclosed in US patent No. 5,057,540.

Non-reactogenic adjuvant formulations containing QS21 have been described
20 previously (WO 96/33739). Such formulations comprising QS21 and cholesterol have been shown to be successful TH1 stimulating adjuvants when formulated together with an antigen.

Further adjuvants which are preferential stimulators of TH1 cell response include
25 immunomodulatory oligonucleotides, for example unmethylated CpG sequences as disclosed in WO 96/02555.

Combinations of different TH1 stimulating adjuvants, such as those mentioned hereinabove, are also contemplated as providing an adjuvant which is a preferential

stimulator of TH1 cell response. For example, QS21 can be formulated together with 3D-MPL. The ratio of QS21 : 3D-MPL will typically be in the order of 1 : 10 to 10 : 1; preferably 1:5 to 5 : 1 and often substantially 1 : 1. The preferred range for optimal synergy is 2.5 : 1 to 1 : 1 3D-MPL: QS21.

5

Preferably a carrier is also present in the vaccine composition according to the invention. The carrier may be an oil in water emulsion, or an aluminium salt, such as aluminium phosphate or aluminium hydroxide.

- 10 A preferred oil-in-water emulsion comprises a metabolisable oil, such as squalene, alpha tocopherol and Tween 80. In a particularly preferred aspect the antigens in the vaccine composition according to the invention are combined with QS21 and 3D-MPL in such an emulsion. Additionally the oil in water emulsion may contain span 85 and/or lecithin and/or tricaprylin.

15

Typically for human administration QS21 and 3D-MPL will be present in a vaccine in the range of 1µg - 200µg, such as 10-100µg, preferably 10µg - 50µg per dose.

Typically the oil in water will comprise from 2 to 10% squalene, from 2 to 10% alpha tocopherol and from 0.3 to 3% tween 80. Preferably the ratio of squalene: alpha

- 20 tocopherol is equal to or less than 1 as this provides a more stable emulsion. Span 85 may also be present at a level of 1%. In some cases it may be advantageous that the vaccines of the present invention will further contain a stabiliser.

- 25 Non-toxic oil in water emulsions preferably contain a non-toxic oil, e.g. squalene or squalene, an emulsifier, e.g. Tween 80, in an aqueous carrier. The aqueous carrier may be, for example, phosphate buffered saline.

A particularly potent adjuvant formulation involving QS21, 3D-MPL and tocopherol in an oil in water emulsion is described in WO 95/17210.

The present invention also provides a polyvalent vaccine composition comprising a vaccine formulation of the invention in combination with other antigens, in particular antigens useful for treating cancers, autoimmune diseases and related conditions. Such a
5 polyvalent vaccine composition may include a TH-1 inducing adjuvant as hereinbefore described.

While the invention has been described with reference to certain BASB047, BASB054, BASB068 and BASB069 polypeptides and polynucleotides, it is to be understood that this
10 covers fragments of the naturally occurring polypeptides and polynucleotides, and similar polypeptides and polynucleotides with additions, deletions or substitutions which do not substantially affect the immunogenic properties of the recombinant polypeptides or polynucleotides.

15 The antigen can also be delivered in the form of whole bacteria (dead or alive) or as subcellular fractions, these possibilities do include *N.meningitidis* itself.

Compositions, kits and administration

20 In a further aspect of the invention there are provided compositions comprising a BASB047, BASB054, BASB068 or BASB069 polynucleotide and/or a BASB047, BASB054, BASB068 or BASB069 polypeptide for administration to a cell or to a multicellular organism.

25 The invention also relates to compositions comprising a polynucleotide and/or a polypeptide discussed herein or their agonists or antagonists. The polypeptides and polynucleotides of the invention may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to an individual. Such compositions comprise, for instance, a media additive

or a therapeutically effective amount of a polypeptide and/or polynucleotide of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration. The invention further
5 relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides, polynucleotides and other compounds of the invention may be employed
10 alone or in conjunction with other compounds, such as therapeutic compounds.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.
15

In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

20 In a further aspect, the present invention provides for pharmaceutical compositions comprising a therapeutically effective amount of a polypeptide and/or polynucleotide, such as the soluble form of a polypeptide and/or polynucleotide of the present invention, agonist or antagonist peptide or small molecule compound, in combination with a pharmaceutically acceptable carrier or excipient. Such carriers include, but are not limited to, saline, buffered
25 saline, dextrose, water, glycerol, ethanol, and combinations thereof. The invention further relates to pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention.

Polypeptides, polynucleotides and other compounds of the present invention may be employed alone or in conjunction with other compounds, such as therapeutic compounds.

0989746 123101

The composition will be adapted to the route of administration, for instance by a systemic or an oral route. Preferred forms of systemic administration include injection, typically by intravenous injection. Other injection routes, such as subcutaneous, intramuscular, or intraperitoneal, can be used. Alternative means for systemic administration include transmucosal and transdermal administration using penetrants such as bile salts or fusidic acids or other detergents. In addition, if a polypeptide or other compounds of the present invention can be formulated in an enteric or an encapsulated formulation, oral administration may also be possible. Administration of these compounds may also be topical and/or localized, in the form of salves, pastes, gels, solutions, powders and the like.

For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be from 0.01 mg/kg to 10 mg/kg, typically around 1 mg/kg. The physician in any event will determine the actual dosage which will be most suitable for an individual and will vary with the age, weight and response of the particular individual. The above dosages are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

The dosage range required depends on the choice of peptide, the route of administration, the nature of the formulation, the nature of the subject's condition, and the judgment of the attending practitioner. Suitable dosages, however, are in the range of 0.1-100 $\mu\text{g/kg}$ of subject.

A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.5-5 microgram/kg of antigen, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks. With the indicated dose range, no adverse toxicological effects will

be observed with the compounds of the invention which would preclude their administration to suitable individuals.

Wide variations in the needed dosage, however, are to be expected in view of the variety of compounds available and the differing efficiencies of various routes of administration. For example, oral administration would be expected to require higher dosages than administration by intravenous injection. Variations in these dosage levels can be adjusted using standard empirical routines for optimization, as is well understood in the art.

10 Sequence Databases, Sequences in a Tangible Medium, and Algorithms

Polynucleotide and polypeptide sequences form a valuable information resource with which to determine their 2- and 3-dimensional structures as well as to identify further sequences of similar homology. These approaches are most easily facilitated by storing the sequence in a computer readable medium and then using the stored data in a known macromolecular structure program or to search a sequence database using well known searching tools, such as the GCG program package.

Also provided by the invention are methods for the analysis of character sequences or strings, particularly genetic sequences or encoded protein sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and similarity analysis, DNA, RNA and protein structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, codon usage analysis, nucleic acid base trimming, and sequencing chromatogram peak analysis.

A computer based method is provided for performing homology identification. This method comprises the steps of: providing a first polynucleotide sequence comprising the sequence of a polynucleotide of the invention in a computer readable medium; and

comparing said first polynucleotide sequence to at least one second polynucleotide or polypeptide sequence to identify homology.

- A computer based method is also provided for performing homology identification, said
- 5 method comprising the steps of: providing a first polypeptide sequence comprising the sequence of a polypeptide of the invention in a computer readable medium; and comparing said first polypeptide sequence to at least one second polynucleotide or polypeptide sequence to identify homology.
- 10 All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent application to which this application claims priority is also incorporated by reference
- 15 herein in its entirety in the manner described above for publications and references.

DEFINITIONS

- "Identity," as known in the art, is a relationship between two or more polypeptide sequences
- 20 or two or more polynucleotide sequences, as the case may be, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular*
- 25 *Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heine, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J.,

- eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Methods to determine identity are designed to give the largest match between the sequences tested. Moreover, methods to determine identity are codified in publicly available computer programs. Computer program methods to
- 5 determine identity between two sequences include, but are not limited to, the GAP program in the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN (Altschul, S.F. et al., *J. Mol. Biol.* 215: 403-410 (1990), and FASTA(Pearson and Lipman *Proc. Natl. Acad. Sci. USA* 85; 2444-2448 (1988). The BLAST family of programs is publicly available from NCBI and other sources
- 10 (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990). The well known Smith Waterman algorithm may also be used to determine identity.

Parameters for polypeptide sequence comparison include the following:

- 15 Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)
Comparison matrix: BLOSSUM62 from Henikoff and Henikoff,
Proc. Natl. Acad. Sci. USA. 89:10915-10919 (1992)
Gap Penalty: 8
Gap Length Penalty: 2
- 20 A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Parameters for polynucleotide comparison include the following:

- 25 Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)
Comparison matrix: matches = +10, mismatch = 0
Gap Penalty: 50
Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the default parameters for nucleic acid comparisons.

5 A preferred meaning for "identity" for polynucleotides and polypeptides, as the case may be, are provided in (1) and (2) below.

(1) Polynucleotide embodiments further include an isolated polynucleotide comprising a polynucleotide sequence having at least a 50, 60, 70, 80, 85, 90, 95, 97 or 100% identity to the reference sequence of SEQ ID NO:1, wherein said polynucleotide
10 sequence may be identical to the reference sequence of SEQ ID NO:1 or may include up to a certain integer number of nucleotide alterations as compared to the reference sequence, wherein said alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference
15 nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:1 by the integer defining the percent identity divided by 100 and then subtracting that
20 product from said total number of nucleotides in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \bullet y),$$

wherein n_n is the number of nucleotide alterations, x_n is the total number of nucleotides
25 in SEQ ID NO:1, y is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and \bullet is the symbol for the multiplication operator, and wherein any non-integer product of x_n and y is rounded down to the nearest integer prior to subtracting it from x_n . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or

frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

- By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1, that is it may be 100% identical, or it may include up to a certain integer number of nucleic acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one nucleic acid deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference polynucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleic acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleic acid alterations for a given percent identity is determined by multiplying the total number of nucleic acids in SEQ ID NO:1 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of nucleic acids in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \cdot y),$$

- wherein n_n is the number of nucleic acid alterations, x_n is the total number of nucleic acids in SEQ ID NO:1, y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., \cdot is the symbol for the multiplication operator, and wherein any non-integer product of x_n and y is rounded down to the nearest integer prior to subtracting it from x_n .
- (2) Polypeptide embodiments further include an isolated polypeptide comprising a polypeptide having at least a 50, 60, 70, 80, 85, 90, 95, 97 or 100% identity to a polypeptide reference sequence of SEQ ID NO:2, wherein said polypeptide sequence may be identical to the reference sequence of SEQ ID NO:2 or may include up to a certain integer number of amino acid alterations as compared to the reference sequence, wherein

said alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions,

- 5 interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence, and wherein said number of amino acid alterations is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

10

$$n_a \leq x_a - (x_a \bullet y),$$

- wherein n_a is the number of amino acid alterations, x_a is the total number of amino acids in SEQ ID NO:2, y is 0.50 for 50%, 0.60 for 60%, 0.70 for 70%, 0.80 for 80%, 0.85 for
15 85%, 0.90 for 90%, 0.95 for 95%, 0.97 for 97% or 1.00 for 100%, and \bullet is the symbol for the multiplication operator, and wherein any non-integer product of x_a and y is rounded down to the nearest integer prior to subtracting it from x_a .

- By way of example, a polypeptide sequence of the present invention may be identical to
20 the reference sequence of SEQ ID NO:2, that is it may be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the percent identity is less than 100% identity. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and
25 wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino

acids in SEQ ID NO:2 by the integer defining the percent identity divided by 100 and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or:

$$n_a \leq x_a - (x_a \bullet y),$$

5

wherein n_a is the number of amino acid alterations, x_a is the total number of amino acids in SEQ ID NO:2, y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and \bullet is the symbol for the multiplication operator, and wherein any non-integer product of x_a and y is rounded down to the nearest integer prior to subtracting it from x_a .

10

"Individual(s)," when used herein with reference to an organism, means a multicellular eukaryote, including, but not limited to a metazoan, a mammal, an ovid, a bovid, a simian, a primate, and a human.

15 "Isolated" means altered "by the hand of man" from its natural state, *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a polynucleotide or a polypeptide naturally present in a living organism is not "isolated," but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. Moreover, a polynucleotide or
20 polypeptide that is introduced into an organism by transformation, genetic manipulation or by any other recombinant method is "isolated" even if it is still present in said organism, which organism may be living or non-living.

"Polynucleotide(s)" generally refers to any polyribonucleotide or polydeoxyribonucleotide,
25 which may be unmodified RNA or DNA or modified RNA or DNA including single and double-stranded regions.

"Variant" refers to a polynucleotide or polypeptide that differs from a reference polynucleotide or polypeptide, but retains essential properties. A typical variant of a

- polynucleotide differs in nucleotide sequence from another, reference polynucleotide. Changes in the nucleotide sequence of the variant may or may not alter the amino acid sequence of a polypeptide encoded by the reference polynucleotide. Nucleotide changes may result in amino acid substitutions, additions, deletions, fusions and
- 5 truncations in the polypeptide encoded by the reference sequence, as discussed below. A typical variant of a polypeptide differs in amino acid sequence from another, reference polypeptide. Generally, differences are limited so that the sequences of the reference polypeptide and the variant are closely similar overall and, in many regions, identical. A variant and reference polypeptide may differ in amino acid sequence by
- 10 one or more substitutions, additions, deletions in any combination. A substituted or inserted amino acid residue may or may not be one encoded by the genetic code. A variant of a polynucleotide or polypeptide may be a naturally occurring such as an allelic variant, or it may be a variant that is not known to occur naturally. Non-naturally occurring variants of polynucleotides and polypeptides may be made by mutagenesis
- 15 techniques or by direct synthesis.

"Disease(s)" means any disease caused by or related to infection by a bacteria, including , for example, upper respiratory tract infection, invasive bacterial diseases, such as bacteremia and meningitis.

EXAMPLES

The examples below are carried out using standard techniques, which are well known and routine to those of skill in the art, except where otherwise described in detail. The examples are illustrative, but do not limit the invention.

Example 1

The BASB047 gene in *N.meningitidis* strain ATCC 13090.

10

The BASB047 gene of *N. meningitidis* strain ATCC 13090 is shown in SEQ ID NO:1. The translation of the BASB047 polynucleotide sequence, shown in SEQ ID NO:2, shows significant similarity to *E. coli* ferric aerobactin receptor precursor (cloacin receptor). The BASB047 polypeptide contains a sequence which has the characteristics of a leader signal sequence. The signal sequence would be cleaved after residue 25 of the sequence shown in SEQ ID NO:2. BASB047 has the characteristics of an outer membrane protein involved iron uptake.

Example 2

20

The BASB054 gene in *N.meningitidis* strain ATCC 13090.

The BASB054 gene of *N. meningitidis* strain ATCC 13090 is shown in SEQ ID NO:3. The translation of the BASB054 polynucleotide sequence, shown in SEQ ID NO:4, shows significant similarity to a *E. coli* organic solvent tolerance protein. The BASB054 polypeptide contains a sequence which has the characteristics of a leader signal sequence. This signal sequence would be cleaved after residue 22 of the SEQ ID NO:4 polypeptide.

Example 3

The BASB068 gene in *N.meningitidis* strain ATCC 13090.

- 5 The BASB068 gene of *N. meningitidis* strain ATCC 13090 is shown in SEQ ID NO:5. The translation of the BASB068 polynucleotide sequence, shown in SEQ ID NO:6, shows significant similarity to *E. coli* AIDA-I protein. The BASB068 polypeptide contains a sequence which has the characteristics of a leader signal sequence. This signal sequence would be cleaved after residue 34 of the polypeptide
- 10 in SEQ ID NO:6. BASB068 has the characteristics of an outer membrane protein.

Example 4

The BASB069 gene in *N.meningitidis* strain ATCC 13090.

- 15 The BASB069 gene of *N. meningitidis* strain ATCC 13090 is shown in SEQ ID NO:7. The translation of the BASB069 polynucleotide sequence, shown in SEQ ID NO:8, shows significant similarity to *E coli* AIDA-I protein. The BASB069 polypeptide contains a sequence which has the characteristics of a leader signal
- 20 sequence. This signal sequence would be cleaved after residue 31 of the sequence of SEQ ID NO:8. BASB069 has the characteristics of an outer membrane protein.

25

Polynucleotide and Polypeptide Sequences

SEQ ID NO:1

Neisseria meningitidis BASB047 polynucleotide sequence from strain ATCC 13090

5 ATGCGTCATTCCCCTATTTTCAATGGTTATCTTTGCCTTTACTAAGTGTGGCAGTAAC
CAGCAGTTGTACGCTCAACCCAATGAGTCATTACCAACGGTTGAATTAGAGCCTGTGGTT
ATTACCATTGATAAGAGCGGTATGGCACTTGCCAATCGTATCACGCAAATGCCCCATACC
ACCAAAGTTATTTATGAAGAGCAAATTCAAGAGCAAGCAACAGGCTCTCGACAGCTTGCC
10 GATGTGATGGCACAGCTCATTCCAAGTTTGGGGGTAAGTAGTGGCACTACCAGTAACTTT
GGGCAAACCATGCACGGTCGTCAAGTGCAATTTTGTAAATGGCGTGCCTTTGACAGGT
TCGCGAGACATCTCTAGACAGCTTAATAGTATCAATCCCAATCAAGTGGCTAGAATTGAA
GTTTTATCAGGAGCAACCAGTATTTATGGGTCTGGAGCAACAGGCGGTTTGATTAATATC
GTTACTAAGTCTGATTTGGAAGAGGAGCAATTTGAAACCCGCATCGGTGTACATGGTAGT
AAATTATCCAGTGAAGGTATCGGTTATCAGGTAGGTGAGAGTGTAGCAGGTGTCAGCGAA
15 AATGGTAATGTCCTTGCACGACTTGATGTCGACTATCGCACACAGGAGGGGCATTTGAT
GCTAACGGTAACGCATCGCTCCTGAGCCTGCCCAAAGTATAAGCAAGACAGCAAAAGC
CTAAGTGTCAATACAAATGTTGATTGGCAACTTGACGACAAGCAAAATATCAATCTGGCA
TTGACGCATTATAACGACAAACAAGATACCGATTATGCACCTGATTATGGTAATCGCCTT
GCGGTGTTGTTTGGAGAAAAGCCTTCATTAAATGCCATCAAAGGCTTATCATTATCAGAA
20 CAGCCAAAACCAACCAAGCACCTTTAATATCAACTATCATCATGATGATTGTGGGGT
AACACCATCAATACCAATGCTTATTATCGCAGAGAGAAAGGCAGATTTTATCCCTTTGTT
GCCCCGTTTTTCGATCGCCAAAGCCCTGCCTATTTTACAAAGCATGAATTTGCCATCAGCC
ACTTTGGATGCTTATACCAAGGCTCCACAAGCTCGCGCCTATGGGGTGTACAATCCGAA
25 TCTAAGGCAGAGGTACTAGGGCGTGTCCCTAATTTGAATAAGCCAAAAGAGCCCTATTT
TAA

SEQ ID NO:2

Neisseria meningitidis BASB047 polypeptide sequence deduced from the polynucleotide sequence of SEQ ID NO:1

30 MRSHYFQWLSLPLLSVAVTQQLYAQPNESLPTVELEPVVITIDKSGMALANRITQMPHT
TKVIYEEQIQEQATGSRQLADVMAQLIPSLGVSSGTTSNFGQTMHGRQVQFLNGVPLTG
SRDISRQLNSINPNQVARIEVLSGATSIYGSATGGLINIVTKSDLEEEQFETRIGVHGS
KLSSEGIGYQVGQSVAGVSENGVNLARLDVDYRTTGAFFDANGKRIAPEPAQTDKQDSKS
35 LSVNTNVDWQLDDKQINLALTHYNDKQD TDYAPDYGNRLAVLFGEKPSLNAIKGLSLSE
QPKTTKSTFNINYHDDLWGNTINTNAYRREKGRFYFVAPFSIAKALPILQSMNLPSA
TLDAYTKAPQARAYGVLQSESKEVLGRVPLNPKRALF

SEQ ID NO:3

Neisseria meningitidis BASB054 polynucleotide sequence from strain ATCC 13090

40 TTGGCTCGTTTATTTTCACTCAAACCACTGGTGCTGGCATTGGGCTTCTGCTTCGGCAGC
CATTGCGCCCGCCGATGCCGTTGCGGCGGAGGAAACGGACAATCCGACCGCCGGAGGA
AGTGTTCGAGCGTGTCCGAACCCATGCAGCCTGCCGCGCTGAGCCTCGGTTTCGACCTGC
CTGTTTTGCAGTAACGAAAGCGGCAACCCGAAAAACCGAATCTGCCGTCAAAGGAAGC

GGCGAAGGGCCTGTGCCCCGAAAACACACGCGAATTGTGCGCCGACAAGGTGGAAGGGCAG
 TCGCAGGTCAAGGTACGCGCGGAGGGCGGCGTTCGTTGTGCAACGCAACCGGACGACCCTT
 AATGCCGACTGGGCGGATTACGACCAGTCGGGCGACACCGTTACCGTAGGCGACCGGTTT
 5 GCCCTCCAACAGGACGGTACGCTGATTGCGGGCGAAACCTGACCTACAATCTCGAGCAG
 CAGACCGGCGAAGCGCACAACTGCCGATGGAACCGAACAAGGCGGACGGCGGCTGCAA
 AGCGTCAGCCGACCGCCGAAATGTTGGGCGAAGGGCATTACAACTGACGGAAACCCAA
 TTCAACACCTGTTCCGCCGGCGATGCCGGCTGGTATGTCAAGGCAGCCTCTGTGCAAGCC
 GATCGGGGAAAAAGGCATAGGCGTTGCCAAACACGCGCCTTCGTGTTGCGCGGCGTTCTT
 10 ATTTCTACACCCCTTGGGCGGACTTCCCGCTTGACGGCAACCGCAAAAGCGGCCTGCTT
 GTTCCCTCACTGTCCGCCGGTTCCGACGGCGTTTTCCCTTTCCGTTCCCTATTATTTCAAC
 CTGCCCCCAATCTCGATGCCACGTTCCGCGCCAGCGTGATCGGCGAACGCGGCGCGGTC
 TTTGACGGGCAGGTACGCTACCTGCGGCCGATTATGCCGGCCAGTCCGACCTGACCTGG
 CTGCCGACGACAAGAAAAGCGGCAGGAATAACCGCTATCAGGCGAAATGGCAGCATCGG
 CACGACATTTCCGACACGCTTCAGGCGGGTGTGATTTCAACCAAGTCTCCGACAGCGGC
 15 TACTACCGCGACTTTTACGGCAACAAAGAAATCGCCGGCAACGTCAACCTCAACCGCCGT
 GTATGGCTGGATTATGGCGGCAGGGCGGCGGGCGGCGAGCCTGAATGCCCGCCTTTCCGTT
 CTGAAATACCAGACGCTGGCAAACCAAAGCGGCTACAAAGACAAACCGTATGCCCTGATG
 CCGCGCCTTTCCGCCGATTGGCGCAAAAACACCGGCAGGGCGCAAAATCGGCGTGTCCGCA
 CAATTTACCCGCTTCAGCCACGACAGCCGCCAAGACGGCAGCCGCCCTCGTCTATATCCC
 20 GACATCAAATGGGATTTACGCAACAGCTGGGGTTACGTCCGTCCCAAACTCGGACTGCAC
 GCCACCTATTACAGCCTCAACCGCTTCGGCAGCCAAGAAGCCGACGCGTCAGCCGCACT
 CTACCCATCGTCAACATCGACAGCGGCATGACCTTCGAACGCAATACGCGGATGTTCCGGC
 GGAGAAGTCTTGCAAACCCCTCGAGCCGCGCCTGTTCTAACAATATATTCTGCCAAATCC
 CAAAACGACCTGCCCAATTTTGATTGCTCGGAAAGCAGCTTCGGCTACGGGCAGCTTTTT
 25 CGTGAAAACCTCTATTACGGCAACGACAGGATTAACACCGCAAACAGCCTTTCCGCCGCC
 GTGCAAAGCCGTATTTTGACGGCGCGACGGGGCAGAGCGTTTCCGCCCGCGCATCGGG
 CAGAAATTTCTACTTCAAAAACGACGAGTCATGCTTGACGGCAGTGTGCGCAAAAAACCG
 CGCAGCCGTTCCGACTGGGTGGCATTCGCTCCAGCGGCATCGGCAGCCGCTTCATCCTC
 GACAGCAGCATCCACTACAACCAAAACGACAAACGCGCCGAGAACTACGCCGTCCGTGCA
 30 AGCTACCGTCCCGCACAGGGCAAAGTGCTGAACGCCCGCTACAAATACGGGCGCAACGAA
 AAAATCTACCTGAAGTCCGACGGTTCTATTTTTACGACAACTCAGCCAGCTCGACCTG
 TCCGCACAATGGCCCCGTGACGCGCAACCTGTGCGCCGTGTCGTTTACAACCTACGGTTTT
 GAAGCAAAAAACCGATAGAGTGTGCGGGGTGCGGAATACAAAAGCAGTTGCGGCTGC
 TGGGGCGCGGGCGGTACGCCCAACGCTACGTTACCGGCGAAAACACCTACAAAAACGCT
 35 GTCTTTTCTCACTTCAGTTGAAAGACCTCAGCAGTGTGCGGAGAAACCCCGCAGACAGG
 ATGGATGTCGCCGTTCCCGGCTATATCCCGCCCACTCTCTTTCCGCCGGACGCAACAAA
 CGGCCCTGA

SEQ ID NO:4

40 *Neisseria meningitidis* BASB054 polypeptide sequence deduced from the polynucleotide
 sequence of SEQ ID NO:3

MARLFSCLKPLVLALGFCFGTHCAAADAVAAEETDNPTAGGSVRSVSEPMQFAGLSLGSTC
 LFCSNESGKPEKTESAVKSGEGPVPENHTRIVADKVEGQSQVKVRAEGGVVVERNRTTL
 NADWADYDQSGDTVTVGDRFALQDGTLLIRGETLTYNLEQQTGEAHNVRMETEQGGRRLQ
 45 SVSRTAEMLGEGHYKLTTETQFNTCSAGDAGWYVKAASVEADREKIGIVAKHAAFVFGGVP
 IFYTPWADFPLDGNRKSGLLVPSLSAGSDGVSLSVPYFNLAPNLDAFAPSVIGERGAV
 FDGQVRYLRPDYAGQSDLTWLPHDKKSGRNNRYQAKWQHRHDSDTLQAGVDFNQVSDSG
 YYRDFYGNKEIAGNVNLRNRVWLDYGGRAAGGSLNAGLSVLKYQTLANQSGYKDKPYALM
 PRLSADWRKNTGRAQIGVSAQFTRFSHDSRQDGSRLVVYPDIKWDFSNSWGYVRPKLGLH
 50 ATYYSLNRFSGQEARRVSRTLPIVNIDSGMTFERNTRMFGGEVLQTLERLFYNYIPAKS

QNDLPNFDSSSESSFGYGQLFRENLYYGNDRIANTANSLSAVQSRILDGATGAERFRAGIG
 QKFYFKNDVMDLGSVGKKPRSRSDWVAFASSGIGSRFILDSSIHYNQNDKRAENYAVGA
 SYRPAQKVLNARYKYGRNEKIYKSDGSYFYDKLSQLDLQAQWPLTRNLSAVVRYNYGF
 EAKKPIEVLAGA EYKSSCGCWGAGVYAQRYVTGENTYKNAVFFSLQLKDLSSVGRNPADR
 5 MDVAVPGYIPAHSLSAGRNRKP

SEQ ID NO:5

Neisseria meningitidis BASB068 polynucleotide sequence from strain ATCC 13090

ATGAAACTCGAAGCAAGCAAGCAAGCAAGCAGAAGTTAAAAAATCATTATTATA
 10 AGTCTATTTTTTCTATTCTTTATACCTCTCCGCTTTTGCGTGTGATTACGTTTACGAC
 AAAACCAAGCTCACTGATGATGAAATTACCCGCTTAAAAAACTCCGCGATAGAAATAGT
 GAATATTGGAAAGAAGAACTTATCACATAAAAAGTAACAACCGAGTTTATCCAAACATT
 CCGCATTTATCCCTAAACATCCTTTTCGATCCATTTCGAAAACATCAATAATTCAAAAAGG
 ATTTCTTTTATGACAAAGAATACACTGAAGATTACCTTGTGGTTTTGCTCAAGGTTTA
 15 GCGGTTGCAAAAAGAAATGGGGAAACAGAAAAACCAATACGGCAATATTTTAAGGAATGT
 TTAACACTGGGAAATATAGTGATGATACTTGCAAATCTCAACAATCTATTCTACAGTA
 AGAAGTGATATTTTCGCCCTAAATACGAAAATAAAAAATAGCCATATCAACAGCGAAATT
 TTCGCTGTGCGTAATTATACAAAATTGATGTACTCAGCCCAACATCATTCTATTTGGTCA
 GAGCATCTCTATTCCAATTCAGAATTATCTCTTGACGTTGATAACTCACACGTTATCGGA
 20 CAAACGATTGATTTGGGAGCATTAGAATTAACAAATCTCTATGGGAACCCCGTTGGAAC
 TCTAATATTGATTATTTAATAACAAAAAATGCTGAAATTCGTTTAACTAAAAGTGAA
 AGTTTACTCGTAAAAGAAGATTATGCTGGCGGAGCTCGTTTTCGTTTTGCTTACGGTCTA
 AAAGATAAAGTCCCTGAAACACCAATTTTAACTTTTGAAAAAATATAACTGGCACATCA
 GATATTATTTTTGAGGGAAAAGCGTTGGATAATTTAAACACCTAGACGGGCATCAAATT
 25 ATCAAAGTAAATGGCACAGCAGATAAACACGCATTCCGTCCTTCTGGCAAACACCAAAG
 GGAATTTATACGCTTTCTTTTACAACAACGCCAGAGGGCTTTTTTACCAGTGAAGAA
 CGCGATGATATTGCGATTTATGCACAACAAGCCCAAGCCGCCAATACCTTATTTCGCTTG
 CGTTTAAACGACAAAAACAGCGATATTTTTGACCGCACTTTACCGCGCAAAGGCTTGTGG
 TTACGTGTGATTGACGGACATTCCAGCCAATGGGTACAAGGCAAAACGGCACCAGTAGAA
 30 GGAAATCGTAAAGGCATACAACTTGGTGGCGATGTTTTCTCATTGCAAAATCACAATAT
 CAACTTTCCGTTGGCTTAATGGGCGGACAAGCAGAACAACGCAGTACTTTCCGCAACCCA
 GATACAGACAATCTTACAACGGGAAATGTGAAAGGCTTTGGTGCAGGCGTTTACGCCACT
 TGGCATCAGCTTCAGGACAAACAGACAGGTGCGTATGCGGATAGCTGGGTACAATATCAA
 CGTTTCCGCCACCGTATCAACACTGAAGATGGTACAGAACGTTTTACTTCAAAAGGTATT
 35 ACTGCCTCAATTGAAGCAGGTTACAACGCTTTATTGGCGGAACACGTAATAAAAAGGGC
 AACAGCCTTCGTGTTTACCTACAACCACAGGCGCAATTGACTTATTTGGGGGTAAACGGA
 AAATTCAGCGATAGCGAAAATGCCACGTGAATTTACTTGGCTCTCGCCAATTACAAAGC
 CGAGTGGGCGTTCAAGCTAAAGCTCAATTTGCTTTCACTAATGGCGTCACTTTCCAACCA
 TTTGTTTCCGTCAATTCAATCTACCAACAAAAACCTTTTCGGGGTAGAAATGGACGGAGAA
 40 CGTCGAGTGATAAACAACAAAAACCGCGATTGAAAGCCAATTAGGCGTTGCGGTAAAAATT
 AAATCTCACTTAACTTTACAAGCAACATTCAACCGCCAAACAGGCAAACATCATCAAGCT
 AAACAAGGCGCATTGAATTTACAGTGACGTTTTTAA

SEQ ID NO:6

45 *Neisseria meningitidis* BASB068 polypeptide sequence deduced from the polynucleotide
 sequence of SEQ ID NO:5

MKLEASKQASKQKFKKSFIISLFFSILYTSPLLAVDYVYDKTKLTDDEITRLKKLRDRNS

EYWKEETYHIKSNNRVYPNIPALFPKHPFDPFENINNSKRISFYDKEYTEDYLVGFAQGL
 GVAKRNGETEKPIRQYFKECLNTGKYSDDTCKSQSIPTVRSDIFALNTKIKNSHINSEI
 FAVGNYTKLMYSAQHHSIWSEHLYSNSLSLDVDNSHVIGQIDLGALELTNSLWEPRWN
 SNIDYLITKNAEIRFNTKSESLLVKEDYAGGARFRFAYGLKDKVPETPILTFEKNITGTS
 5 DIIFEGKALDNLKHLDDGHQIIKVNGTADKHAFLSGKHQKGIYTLSQLQRPEGFFTKVQE
 RDDIAIYAQQAQAANTLFALELNDKNSDIFDRTLPRKGLWLRVIDGHSSQWVQKGTAPVE
 GNRKGIQLGGDVFSLQNHNYQLSVGLMGGQAEQRSTFRNPDTNLTGTVKGFAGVYAT
 WHQLQDKQGTAYADSWVQYQFRHRINTEDGTERFTSKGITASIEAGYNALLAEHVTKKG
 10 NSLRVYLQPPAQLTYLGVNGKFSDSENAHVNLGSRQLQSRVGVQAKAQFAFTNGVTFQP
 FVSVNSIYQQKPFVEMDGERRVINNKTAIESQLGVAVKIKSHLTLQATFNRQTGKHHQA
 KQGALNLQWTF

SEQ ID NO:7

Neisseria meningitidis BASB069 polynucleotide sequence from strain ATCC 13090

15 ATGACACTGAAAGCAAGCAAGCAAGCAAGCGGTGCGGTAAATCTATTAACATTATCTGTT
 TTATCGCTGTTTTGCACGCCATATGTTTGTGGTTCGGATGCGTACGATCCCGTCAAAGAA
 GCCGAGATTAAAAACAAATTTATTTTGAAGCGGCGGAAGACAGAAATCCACGTTTGG
 CGCGGCCCGTGACGATATCTTTTGATTGCTTCGGTATGTTTACAGAGCTCAGCTTGGTTCA
 AATACTCGTTCTACCAAATCGGCGACGATGCCGATTTTTTCATTTTCAGACAAGCCGAAA
 20 CCCGGCACTTCCCATATTTTTCCAGCGGTAAAACCGATCAAATTCATCCGAATATGGG
 TATGACGAAATCAATATCCAAGGTAAAACTACAATAGCGGCATACTCGCCGTCGATAAT
 ATGCCCCGTGTTTAAAGAAATATATTACAGATACTTACGGGGATAATTTAAAGGATGCGGTT
 AAGAAGCAATTACAGGATTTATACAAAACAGACCCGAAGCTTGGGAAGAAAATAAAAAA
 CGGACTGAGGAGGCGTATATAGAACAGCTTGGACCAAAATTTAGTATACTCAAACAGAAA
 25 AACCCCGATTTAATTAATAAATTTGGTAGAAGATTCCGTACTCACTCCTCATAGTAATACA
 TCACAGACTAGTCTCAACAACATCTTCAATAAAAAATTACACGTCAAATCGAAAAACAA
 TCCCACGTCGCGGACAGGTGTTGGAACTGACCAAGATGACGCTGAAAGATTCCCTTTGG
 GAACCGCGCCGCAATTCCGACATCCATACGCTGGAACTTCCGATAATGCCCGCATCCGC
 CTGAACACGAAAGATGAAAACTGACCGTCCATAAAGCGTATCAGGGCGGCGCGGATTTT
 30 CTGTTTCGGCTACGACGTGCGGGAGTTCGGACGAACCCGCCCTGACCTTTGAACAAAACGTC
 AGCGGAAAATCCGGCGTGGTTTTTGGAAACGCCGCGGAAAATCTGAAAACGCTCGACGGG
 CGCAAACTGATTGCGGCGGAAAAGGCAGACCCATAATTGCTTTGCGTTTAAACAAAATTAC
 CGGCAGGGACTGTACGAATTATTGCTCAAGCAATGCGAAGGCGGATTTTGCTTGGGTGTG
 CAGCGTTTGGCTATCCCTGAGGCGGAAGCGGTTTTATATGCCCAACAGGCTTATGCGGCA
 35 AATACTTTGTTTGGGCTGCGTGCCGCCGACAGGGGCGACGACGTGTATGCCGCCGATCCG
 TCCCGTCAAAAATTGTGGCTGCGCTTCATCGGCGGCGCGGTGCGATCAAATATACGGGGC
 GGCGCGGCTGCGGACGGGCGGCGCAAAGGCGTGCAATCGGCGGTGAGGTGTTTGTACGG
 CAAAATGAAGGCAGTCGGCTGGCAATCGGCGTGATGGGCGGCGAGGCTGGCCAGCACGCA
 TCAGTCAACGGCAAAGGCGGTGCGGCAGGCAGTTATTTGCATGTTTATGGCGGGGGTGT
 40 TATGCTGCGTGGCATCAGTTGCGCGATAAACAAACGGGTGCGTATTTGGACGGCTGGTTG
 CAATACCAACGTTTCAAACACCGCATCAATGATGAAAACCGTGCGGAACGCTACAAAACC
 AAAGGTTGGACGGCTTCTGTGCAAGGCGGCTACAACGCGCTTGTGGCGGAAGGCGTTGTC
 GGAAAAGGCAATAATGTGCGTTTTTACCTGCAACCGCAGGCGCAGTTTACCTACTTGGGC
 GTAAACGGCGGCTTTACCGACAGCGAGGGGACGGCGGTGCGACTGCTCGGCAGCGGTGAG
 45 TGGCAAAGCCGCGCGGCATTTCGGGCAAAAACCGTTTTGCTTTGCGTAACGGTGTCAAT
 CTTCAGCTTTTTCGCGTTTTTAATGTTTTGCACAGGTCAAATCTTTCGGCGTGGAATG
 GACGGCGAAAAACAGACGCTGGCAGGCAGGACGGCGCTCGAAGGGCGGTTTCGGCATTGAA
 GCCGGTTGGAAAGGCCATATGTCCGCACGCATCGGATACGGCAAAAGGACGGACGGCGAC
 AAAGAAGCCGCATTGTGCTCAAATGGCTGTTTTGA

SEQ ID NO:8

Neisseria meningitidis BASB069 polypeptide sequence deduced from the polynucleotide sequence of SEQ ID NO:7

5 MTLKASKQASGRVNLLTSLVLSLFCPTPYVCGSDAYDPVKEAEIKNKFILEAAEDRNSHW
RGPCSI SFDCFGMFRAQLGSNTRSTKIGDDADFSFSDKPKPGTSHYFSSGKTDQNSSEYG
YDEINI QGKNYNSGILAVDNMPVVKYITDTYGDNLKDAVKKQLQDLYKTRPEAWENKK
RTEEAYIEQLGPKFSILKQKNPDLINKLVEDSVLTPHSNTSQTSLNNIFNKKLHVKIENK
SHVAGQVLELTKMTLKDSLWEPRRHSDIHTLETSDNARIRLNTKDEKLTVHKAYQGGADF
10 LFGYDVRESDEPALTFEQNVSGKSGVVLERRPENLKTLDGRKLIAAEKADPNSFAFKQNY
RQGLYELLLKQCEGGFCLGVQRLAIPAEAVLYAQQAYAANTLFGRLAADRGDDVYAADP
SRQKLWLRFIGGRSHQNIIRGGAAADGRRKGVQIGGEVFVRQNEGSRLAIGVMGGRAGQHA
SVNGKGAAGSYLHGYGGGVYAAWHQLRDKQTGAYLDGWLQYQRFKHRINDENRAERYKT
KGWTASVEGGYNALVAEGVVGKGNVRFYLPQAQFTYLGVNNGGFTDSEGTAVGLLGSGQ
15 WQSRAGIRAKTRFALRNGVNLQPFAAFNVLHRSKSFVEMDGEKQTLAGRTALEGRFGIE
AGWKGHMSARIGYGKRTDGDKEAALS LKWLF

Deposited materials

A deposit containing a *Neisseria meningitidis* Serogroup B strain has been deposited with the American Type Culture Collection (herein "ATCC") on June 22, 1997 and assigned
5 deposit number 13090. The deposit was described as *Neisseria meningitidis* (Albrecht and Ghon) and is a freeze-dried, 1.5-2.9 kb insert library constructed from *N. meningitidis* isolate. The deposit is described in Int. Bull. Bacteriol. Nomencl. Taxon. 8: 1-15 (1958).

The *Neisseria meningitidis* strain deposit is referred to herein as "the deposited strain" or as
10 "the DNA of the deposited strain."

The deposited strain contains the full length BASB047, BASB054, BASB068 and
BASB069 genes. The sequence of the polynucleotides contained in the deposited strain, as
well as the amino acid sequence of any polypeptide encoded thereby, are controlling in the
15 event of any conflict with any description of sequences herein.

The deposit of the deposited strain has been made under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-organisms for Purposes of Patent Procedure. The strain will be irrevocably and without restriction or condition released to the
20 public upon the issuance of a patent. The deposited strain is provided merely as convenience to those of skill in the art and is not an admission that a deposit is required for enablement, such as that required under 35 U.S.C. §112.

**INDICATIONS RELATING TO DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on page <u>84</u> , line <u>3-22</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution AMERICAN TYPE CULTURE COLLECTION	
Address of depositary institution (including postal code and country) 10801 UNIVERSITY BLVD, MANASSAS, VIRGINIA 20110-2209, UNITED STATES OF AMERICA	
Date of deposit 22 June 1997 (22.06.97)	Accession Number 13090
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
In respect of those designations where a European Patent is sought, a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European Patent or until the date on which the application has been refused or withdrawn, only by issue of such a sample to an expert nominated by the person requesting the sample.	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)	
The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g. "Accession Number of Deposit")	

<p align="center">For receiving Office use only</p> <div style="border: 1px solid black; padding: 5px;"> <input checked="" type="checkbox"/> This sheet was received with the international application <div style="display: flex; justify-content: space-around; font-weight: bold; font-size: 1.2em;"> 19 JAN 2000 (19. 01 2000) </div> </div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> Authorized officer <div style="display: flex; align-items: center;"> M. Legendre </div> </div>	<p align="center">For International Bureau use only</p> <div style="border: 1px solid black; padding: 5px;"> <input type="checkbox"/> This sheet was received by the International Bureau on: </div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;"> Authorized officer </div>
--	---

CLAIMS

1. An isolated polypeptide comprising an amino acid sequence which has at least 85%
5 identity to an amino acid sequence selected from the group consisting of: SEQ ID NO:2,
SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8.
2. An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at
least 95% identity to the amino acid sequence selected from the group consisting of: SEQ
10 ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8.
3. The polypeptide as claimed in claim 1 comprising the amino acid sequence selected
from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID
15 NO:8.
4. An isolated polypeptide of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID
NO:8.
5. An immunogenic fragment of the polypeptide as claimed in any one of claims 1 to 4 in
20 which the immunogenic activity of said immunogenic fragment is substantially the same
as that of the polypeptide of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID
NO:8.
6. An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide
25 that has at least 85% identity to the amino acid sequence of SEQ ID NO:2,4,6 or 8 over the
entire length of SEQ ID NO:2,4,6 or 8 respectively; or a nucleotide sequence
complementary to said isolated polynucleotide.

7. An isolated polynucleotide comprising a nucleotide sequence that has at least 85% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO:2,4,6 or 8 over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide.
- 5
8. An isolated polynucleotide which comprises a nucleotide sequence which has at least 85% identity to that of SEQ ID NO:1,3,5 or 7 over the entire length of SEQ ID NO:1,3,5 or 7 respectively; or a nucleotide sequence complementary to said isolated polynucleotide.
- 10
9. The isolated polynucleotide as claimed in any one of claims 6 to 8 in which the identity is at least 95% to SEQ ID NO:1,3,5 or 7.
10. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8.
- 15
11. An isolated polynucleotide comprising the polynucleotide of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:7.
12. An isolated polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8 obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7 or a fragment thereof.
- 20
13. An expression vector or a recombinant live microorganism comprising an isolated polynucleotide according to any one of claims 6 to 12.
- 25
14. A host cell comprising the expression vector of claim 13 or a subcellular fraction or a membrane of said host cell expressing an isolated polypeptide comprising an amino acid

sequence that has at least 85% identity to the amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8.

15. A process for producing a polypeptide comprising an amino acid sequence that has at least 85% identity to an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8 comprising culturing a host cell of claim 14 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

16. A process for expressing a polynucleotide of any one of claims 6 to 12 comprising transforming a host cell with the expression vector comprising at least one of said polynucleotides and culturing said host cell under conditions sufficient for expression of any one of said polynucleotides.

17. A vaccine composition comprising an effective amount of the polypeptide of any one of claims 1 to 5 and a pharmaceutically acceptable carrier.

18. A vaccine composition comprising an effective amount of the polynucleotide of any one of claims 6 to 12 and a pharmaceutically effective carrier.

19. The vaccine composition according to either one of claims 17 or 18 wherein said composition comprises at least one other *Neisseria meningitidis* antigen.

20. An antibody generated against the polypeptide or immunological fragment as claimed in any one of claims 1 to 5.

21. A method of diagnosing a *Neisseria meningitidis* infection, comprising identifying a polypeptide as claimed in any one of claims 1 to 5, or an antibody that is immunospecific

for said polypeptide, present within a biological sample from an animal suspected of having such an infection.

22. Use of a composition comprising an immunologically effective amount of a
5 polypeptide as claimed in any one of claims 1 to 5 in the preparation of a medicament for use in generating an immune response in an animal.

23. Use of a composition comprising an immunologically effective amount of a
polynucleotide as claimed in any one of claims 6 to 12 in the preparation of a medicament
10 for use in generating an immune response in an animal.

24. A therapeutic composition useful in treating humans with *Neisseria meningitidis*
disease comprising at least one antibody directed against the polypeptide of claims 1 to 5
and a suitable pharmaceutical carrier.
15

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL COMPOUNDS the specification of which (check one)

☐ is attached hereto.

☒ was filed on 19 January 2000 as Serial No. PCT/EP00/00428
and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number	Country	Filing Date	Priority Claimed
9901368.2	Great Britain	22 January 1999	Yes
9901944.0	Great Britain	28 January 1999	Yes
9902086.9	Great Britain	29 January 1999	Yes
9903417.5	Great Britain	15 February 1999	Yes
9903535.4	Great Britain	16 February 1999	Yes

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

Application Number Filing Date

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the

first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

Serial No.	Filing Date	Status
------------	-------------	--------

I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 25,308

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor: 1-10 Jean-Louis RUELLE

Inventor's Signature: [Signature]

Date: Aug 13, 2001

Residence: Rixensart, Belgium BEX

Citizenship: Belgian

Post Office Address: SmithKline Beecham Corporation
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, Pennsylvania 19406-0939

09889746 12201

SEQUENCE LISTING

<110> SmithKline Beecham Biologicals S.A.

<120> Novel compounds

<130> BM45352

<160> 8

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 1203

<212> DNA

<213> *Neisseria meningitidis*

<400> 1

atgcgtcatt cccactat	ttt tcaatgg	tta tctttgc	ctt tactaag	tgt ggcagta	aact	60
cagcagttgt acgctca	acc caatgag	tca ttacca	acgg ttgaatt	aga gcctgt	gggt	120
attaccattg ataagag	cgg tatggc	actt gccaat	cgt taacg	caaat gccccat	acc	180
accaaagtta tttatga	aga gcaaatt	caa gagca	agcaa caggct	cctcg acagct	tggc	240
gatgtgatgg cacagct	cat tccaagt	tttg ggggta	agta gtggc	actac cagta	acttt	300
gggcaaacca tgcacgg	tgc tcaagt	gcaa tttttg	ttaa atggc	gtgc tttg	acaggt	360
tcgcgagaca tctctag	aca gctta	aatagt atcaat	ccca atcaag	tggc taga	aattgaa	420
gttttatcag gagcaac	cag tatttat	ggg tctgg	agcaa caggcg	gttt gatta	aatatc	480
gttactaagt ctgattt	gga agaggag	caa tttgaa	acc gcacgc	gtgt acatg	gtagt	540
aaattatcca gtgaagg	tat cggttat	cag gttagg	tcaga gtgtag	cagg tgtc	agcgaa	600
aatggtaatg tccttgc	acg acttgat	gtc gactat	cgc ccacag	gagg ggcat	ttgat	660
gctaacggta aacgcac	tcg tcctgag	cct gcccaa	actg ataag	caaga cagcaa	aagc	720
ctaagtgtca atacaa	tgt tgattg	caa cttgac	gaca agcaaa	atat caatct	ggca	780
ttgacgcatt ataacg	aaa acaagat	acc gattat	gcac ctgatt	atgg taatcg	cctt	840
gcggtgttgt ttggaga	aaaa gccttc	atta aatgcc	atca aaggc	ttatc attat	cagaa	900
cagccaaaaa ccacca	aaag cacctt	taat atcaac	tatc atcat	gatga tttgt	gggg	960
aacaccatca atacca	atgc ttattat	cgc agagaga	aaag gcagat	ttta tccct	ttgtt	1020
gccccgtttt cgatcg	caa agccct	gcct atttt	acaaa gcatga	attt gccat	cagcc	1080
actttggatg cttata	caa ggctcc	aaa gctcgc	cct atggg	gtgtt acaat	ccgaa	1140
tctaaggcag aggtact	agg gcgtgt	ccct aattt	gaata agccca	aaag agccct	at	1200
taa						1203

<210> 2

<211> 400

<212> PRT

<213> *Neisseria meningitidis*

Table 1. Demographic characteristics of the study population	
Age (years)	Mean (SD)
Male	65.2 (10.5)
Female	68.5 (11.2)
Marital status	
Married	72.5%
Single	27.5%
Education level	
High school or above	65.0%
Below high school	35.0%
Occupation	
Retired	78.0%
Unemployed	22.0%
Income (USD/month)	
< 1000	15.0%
1000-2000	45.0%
> 2000	40.0%
Health status	
Good	60.0%
Fair	40.0%
Poor	10.0%
Comorbidities	
Hypertension	55.0%
Diabetes	30.0%
Cholesterol	45.0%
Arthritis	25.0%
Depression	15.0%
Medication use	
Yes	70.0%
No	30.0%
Healthcare utilization	
Regular visits	65.0%
Emergency visits	10.0%
No visits	25.0%
Health insurance	
Yes	85.0%
No	15.0%
Health literacy	
High	50.0%
Low	50.0%
Health beliefs	
Preventive care	60.0%
Curative care	40.0%
Traditional medicine	10.0%
Health communication	
Active	55.0%
Passive	45.0%
Health information sources	
Family	70.0%
Friends	30.0%
Media	15.0%
Healthcare providers	5.0%
Health status assessment	
Self-rated	60.0%
Physician-rated	40.0%
Health status change	
Improved	55.0%
Stable	35.0%
Deteriorated	10.0%
Health status duration	
< 1 year	15.0%
1-5 years	45.0%
> 5 years	40.0%
Health status severity	
Mild	60.0%
Severe	40.0%
Health status impact	
Low	55.0%
High	45.0%
Health status awareness	
High	60.0%
Low	40.0%
Health status knowledge	
High	55.0%
Low	45.0%
Health status attitude	
Positive	60.0%
Negative	40.0%
Health status behavior	
Active	55.0%
Passive	45.0%
Health status participation	
High	60.0%
Low	40.0%
Health status involvement	
High	55.0%
Low	45.0%
Health status engagement	
High	60.0%
Low	40.0%
Health status commitment	
High	55.0%
Low	45.0%
Health status dedication	
High	60.0%
Low	40.0%
Health status devotion	
High	55.0%
Low	45.0%
Health status loyalty	
High	60.0%
Low	40.0%
Health status integrity	
High	55.0%
Low	45.0%
Health status honesty	
High	60.0%
Low	40.0%
Health status sincerity	
High	55.0%
Low	45.0%
Health status genuineness	
High	60.0%
Low	40.0%
Health status openness	
High	55.0%
Low	45.0%
Health status transparency	
High	60.0%
Low	40.0%
Health status accountability	
High	55.0%
Low	45.0%
Health status responsibility	
High	60.0%
Low	40.0%
Health status reliability	
High	55.0%
Low	45.0%
Health status dependability	
High	60.0%
Low	40.0%
Health status predictability	
High	55.0%
Low	45.0%
Health status consistency	
High	60.0%
Low	40.0%
Health status uniformity	
High	55.0%
Low	45.0%
Health status regularity	
High	60.0%
Low	40.0%
Health status orderliness	
High	55.0%
Low	45.0%
Health status tidiness	
High	60.0%
Low	40.0%
Health status neatness	
High	55.0%
Low	45.0%
Health status cleanliness	
High	60.0%
Low	40.0%
Health status wholeness	
High	55.0%
Low	45.0%
Health status completeness	
High	60.0%
Low	40.0%
Health status perfection	
High	55.0%
Low	45.0%
Health status flawlessness	
High	60.0%
Low	40.0%
Health status impeccability	
High	55.0%
Low	45.0%
Health status praiseworthiness	
High	60.0%

Table 1. Demographic characteristics of the study population	
Age (years)	Mean (SD)
Male	65.2 (10.5)
Female	68.5 (11.2)
Marital status	
Married	72.5%
Single	27.5%
Education level	
High school or above	65.0%
Below high school	35.0%
Occupation	
Retired	78.0%
Unemployed	22.0%
Income (USD/month)	
< 1000	15.0%
1000-2000	45.0%
> 2000	40.0%
Health status	
Good	60.0%
Fair	40.0%
Poor	10.0%
Comorbidities	
Hypertension	55.0%
Diabetes	30.0%
Cholesterol	45.0%
Arthritis	25.0%
Depression	15.0%
Medication use	
Yes	70.0%
No	30.0%
Healthcare utilization	
Regular visits	65.0%
Emergency visits	10.0%
No visits	25.0%
Health insurance	
Yes	85.0%
No	15.0%
Health literacy	
High	50.0%
Low	50.0%
Health beliefs	
Preventive care	60.0%
Curative care	40.0%
Alternative medicine	10.0%
Health communication	
Verbal	75.0%
Written	25.0%
Visual	10.0%
Audio	5.0%
Health education	
Yes	65.0%
No	35.0%
Health promotion	
Yes	70.0%
No	30.0%
Health status assessment	
Good	60.0%
Fair	40.0%
Poor	10.0%
Health status improvement	
Yes	65.0%
No	35.0%
Health status maintenance	
Yes	70.0%
No	30.0%
Health status monitoring	
Yes	65.0%
No	35.0%
Health status evaluation	
Yes	70.0%
No	30.0%
Health status feedback	
Yes	65.0%
No	35.0%
Health status follow-up	
Yes	70.0%
No	30.0%
Health status support	
Yes	65.0%
No	35.0%
Health status assistance	
Yes	70.0%
No	30.0%
Health status guidance	
Yes	65.0%
No	35.0%
Health status advice	
Yes	70.0%
No	30.0%
Health status recommendation	
Yes	65.0%
No	35.0%
Health status suggestion	
Yes	70.0%
No	30.0%
Health status proposal	
Yes	65.0%
No	35.0%
Health status offer	
Yes	70.0%
No	30.0%
Health status presentation	
Yes	65.0%
No	35.0%
Health status demonstration	
Yes	70.0%
No	30.0%
Health status illustration	
Yes	65.0%
No	35.0%
Health status explanation	
Yes	70.0%
No	30.0%
Health status description	
Yes	65.0%
No	35.0%
Health status definition	
Yes	70.0%
No	30.0%
Health status identification	
Yes	65.0%
No	35.0%
Health status recognition	
Yes	70.0%
No	30.0%
Health status understanding	
Yes	65.0%
No	35.0%
Health status knowledge	
Yes	70.0%
No	30.0%
Health status awareness	
Yes	65.0%
No	35.0%
Health status perception	
Yes	70.0%
No	30.0%
Health status feeling	
Yes	65.0%
No	35.0%
Health status thought	
Yes	70.0%
No	30.0%
Health status emotion	
Yes	65.0%
No	35.0%
Health status attitude	
Yes	70.0%
No	30.0%
Health status behavior	
Yes	65.0%
No	35.0%
Health status action	
Yes	70.0%
No	30.0%
Health status response	
Yes	65.0%
No	35.0%
Health status reaction	
Yes	70.0%
No	30.0%
Health status effect	
Yes	65.0%
No	35.0%
Health status result	
Yes	70.0%
No	30.0%
Health status outcome	
Yes	65.0%
No	35.0%
Health status impact	
Yes	70.0%
No	30.0%
Health status influence	
Yes	65.0%
No	35.0%
Health status effectness	

355 360 365
 Pro Gln Ala Arg Ala Tyr Gly Val Leu Gln Ser Glu Ser Lys Ala Glu
 370 375 380
 Val Leu Gly Arg Val Pro Asn Leu Asn Lys Pro Lys Arg Ala Leu Phe
 385 390 395 400

<210> 3

<211> 2409

<212> DNA

<213> *Neisseria meningitidis*

<400> 3

ttggctcggtt	tattttcact	caaaccactg	gtgctggcat	tgggcttctg	cttcggcacg	60
cattgcgccc	ccgccgatgc	cgttgcggcg	gaggaaacgg	acaatccgac	cgccggagga	120
agtgttcgga	gcgtgtccga	acccatgcag	cctgcgggcc	tgagcctcgg	ttcgacctgc	180
ctgtttttgca	gtaacgaaag	cggcaaaccg	gaaaaaacgg	aatctgccgt	caaaggaagc	240
ggcgaagggc	ctgtgcccga	aaaccacacg	cgaattgtcg	ccgacaaggt	ggaagggcag	300
tcgcaggtca	aggtacgcgc	ggagggcggc	gtcgttgtcg	aacgcaaccg	gacgaccctt	360
aatgccgact	gggcggatta	cgaccagtcg	ggcgacaccg	ttaccgtagg	cgaccggttc	420
gccctccaac	aggacggtac	gctgattcgg	ggcgaaaccg	tgacctacaa	tctcgagcag	480
cagaccggcg	aagcgacaaa	cgctccgatg	gaaaccgaac	aaggcggacg	gcggtcgcaa	540
agcgtcagcc	gcaccgccga	aatgttgggc	gaagggcatt	acaaactgac	ggaaacccaa	600
ttcaacacct	gttccgcggg	cgatgcgggc	tggtatgtca	aggcagcctc	tgtcgaagcc	660
gatcgggaaa	aaggcatagg	cgttgccaaa	cacgccgcct	tcgtgttcgg	cggcgttccct	720
atttttctaca	cccttgggc	ggacttcccg	cttgacggca	accgcaaaag	cggcctgctt	780
gttccctcac	tgtccgccgg	ttcggaacgc	gtttcccttt	ccgttcccta	ttatttcaac	840
cttgccccca	atctcgatgc	cacgttcggc	cccagcgtga	tcggcgaaacg	cggcgcggtc	900
tttgacgggc	aggtacgcta	cctgcggccg	gattatgccg	gccagtccga	cctgacctgg	960
ctgccgcacg	acaagaaaag	cggcaggaat	aaccgctatc	aggcgaaatg	gcagcatcgg	1020
cacgacatth	ccgacacgct	tcaggcgggt	gtcgatttca	accaagtctc	cgacagcggc	1080
tactaccgcg	acttttacgg	caacaaagaa	atcgccggca	acgtcaacct	caaccgccgt	1140
gtatggctgg	attatggcgg	cagggcggcg	ggcggcagcc	tgaatgccgg	ccttttcggtt	1200
ctgaaatacc	agacgttggc	aaaccaaagc	ggctacaaag	acaaaccgta	tgccctgatg	1260
ccgcgccttt	ccgccgattg	gcgcaaaaac	accggcaggg	cgcaaatcgg	cgtgtccgca	1320
caatttacc	gcttcagcca	cgacagccgc	caagacggca	gccgcctcgt	cgtctatccc	1380
gacatcaa	gggatttcag	caacagctgg	ggttacgtcc	gtcccaaact	cggactgcac	1440
gccacctatt	acagcctcaa	ccgcttcggc	agccaagaag	cccagcgcgt	cagccgcact	1500
ctaccatcg	tcaacatcga	cagcggcatg	accttcgaac	gcaatacgcg	gatgttcggc	1560
ggagaagtcc	tgcaaacctc	cgagccgcgc	ctgtttctaca	actatattcc	tgccaaatcc	1620
caaaacgacc	tgcccaatth	tgattcgtcg	gaaagcagct	tcggctacgg	gcagcttttt	1680
cgtgaaaacc	tctattacgg	caacgacagg	attaacaccg	caaacagcct	ttccgcgcgc	1740
gtgcaaagcc	gtattttgga	cggcgcgacg	ggggcagagc	gtttccgcgc	cggcatcggg	1800
cagaaattct	acttcaaaaa	cgacgcagtc	atgcttgacg	gcagtgtcgg	caaaaaaccg	1860
cgcagccggt	ccgactgggt	ggcattcgcc	tcagcggca	tcggcagccg	cttcaccttc	1920
gacagcagca	tccactacaa	ccaaaacgac	aaacgcgcgc	agaactacgc	cgtcgggtgca	1980
agctaccgtc	ccgcacaggg	caaagtgtcg	aacgcccgtc	acaaatacgg	gcgcaacgaa	2040
aaaatctacc	tgaagtccga	cggttcctat	ttttacgaca	aactcagcca	gctcgacctg	2100

```

tccgcacaat ggccctgac ggcgaacctg tcggccgtcg tccgttacaa ctacggtttt 2160
gaagccaaaa aaccgataga ggtgctggcg ggtgcggaat acaaaagcag ttgcggctgc 2220
tggggcgcg gcggtgtacgc ccaacgctac gttaccggcg aaaacaccta caaaaacgct 2280
gtctttttct cacttcagtt gaaagacctc agcagtgtcg gcagaaaccc cgcagacagg 2340
atggatgtcg ccgttcccg ctatatcccc gccactctc tttccgccgg acgcaacaaa 2400
cgccctga 2409

```

<210> 4

<211> 802

<212> PRT

<213> *Neisseria meningitidis*

<400> 4

```

Met Ala Arg Leu Phe Ser Leu Lys Pro Leu Val Leu Ala Leu Gly Phe
 1             5             10             15
Cys Phe Gly Thr His Cys Ala Ala Ala Asp Ala Val Ala Ala Glu Glu
      20             25             30
Thr Asp Asn Pro Thr Ala Gly Gly Ser Val Arg Ser Val Ser Glu Pro
      35             40             45
Met Gln Pro Ala Gly Leu Ser Leu Gly Ser Thr Cys Leu Phe Cys Ser
      50             55             60
Asn Glu Ser Gly Lys Pro Glu Lys Thr Glu Ser Ala Val Lys Gly Ser
      65             70             75             80
Gly Glu Gly Pro Val Pro Glu Asn His Thr Arg Ile Val Ala Asp Lys
      85             90             95
Val Glu Gly Gln Ser Gln Val Lys Val Arg Ala Glu Gly Gly Val Val
      100            105            110
Val Glu Arg Asn Arg Thr Thr Leu Asn Ala Asp Trp Ala Asp Tyr Asp
      115            120            125
Gln Ser Gly Asp Thr Val Thr Val Gly Asp Arg Phe Ala Leu Gln Gln
      130            135            140
Asp Gly Thr Leu Ile Arg Gly Glu Thr Leu Thr Tyr Asn Leu Glu Gln
      145            150            155            160
Gln Thr Gly Glu Ala His Asn Val Arg Met Glu Thr Glu Gln Gly Gly
      165            170            175
Arg Arg Leu Gln Ser Val Ser Arg Thr Ala Glu Met Leu Gly Glu Gly
      180            185            190
His Tyr Lys Leu Thr Glu Thr Gln Phe Asn Thr Cys Ser Ala Gly Asp
      195            200            205
Ala Gly Trp Tyr Val Lys Ala Ala Ser Val Glu Ala Asp Arg Glu Lys
      210            215            220
Gly Ile Gly Val Ala Lys His Ala Ala Phe Val Phe Gly Gly Val Pro
      225            230            235            240
Ile Phe Tyr Thr Pro Trp Ala Asp Phe Pro Leu Asp Gly Asn Arg Lys
      245            250            255
Ser Gly Leu Leu Val Pro Ser Leu Ser Ala Gly Ser Asp Gly Val Ser
      260            265            270

```

Leu Ser Val Pro Tyr Tyr Phe Asn Leu Ala Pro Asn Leu Asp Ala Thr
 275 280 285
 Phe Ala Pro Ser Val Ile Gly Glu Arg Gly Ala Val Phe Asp Gly Gln
 290 295 300
 Val Arg Tyr Leu Arg Pro Asp Tyr Ala Gly Gln Ser Asp Leu Thr Trp
 305 310 315 320
 Leu Pro His Asp Lys Lys Ser Gly Arg Asn Asn Arg Tyr Gln Ala Lys
 325 330 335
 Trp Gln His Arg His Asp Ile Ser Asp Thr Leu Gln Ala Gly Val Asp
 340 345 350
 Phe Asn Gln Val Ser Asp Ser Gly Tyr Tyr Arg Asp Phe Tyr Gly Asn
 355 360 365
 Lys Glu Ile Ala Gly Asn Val Asn Leu Asn Arg Arg Val Trp Leu Asp
 370 375 380
 Tyr Gly Gly Arg Ala Ala Gly Gly Ser Leu Asn Ala Gly Leu Ser Val
 385 390 395 400
 Leu Lys Tyr Gln Thr Leu Ala Asn Gln Ser Gly Tyr Lys Asp Lys Pro
 405 410 415
 Tyr Ala Leu Met Pro Arg Leu Ser Ala Asp Trp Arg Lys Asn Thr Gly
 420 425 430
 Arg Ala Gln Ile Gly Val Ser Ala Gln Phe Thr Arg Phe Ser His Asp
 435 440 445
 Ser Arg Gln Asp Gly Ser Arg Leu Val Val Tyr Pro Asp Ile Lys Trp
 450 455 460
 Asp Phe Ser Asn Ser Trp Gly Tyr Val Arg Pro Lys Leu Gly Leu His
 465 470 475 480
 Ala Thr Tyr Tyr Ser Leu Asn Arg Phe Gly Ser Gln Glu Ala Arg Arg
 485 490 495
 Val Ser Arg Thr Leu Pro Ile Val Asn Ile Asp Ser Gly Met Thr Phe
 500 505 510
 Glu Arg Asn Thr Arg Met Phe Gly Gly Glu Val Leu Gln Thr Leu Glu
 515 520 525
 Pro Arg Leu Phe Tyr Asn Tyr Ile Pro Ala Lys Ser Gln Asn Asp Leu
 530 535 540
 Pro Asn Phe Asp Ser Ser Glu Ser Ser Phe Gly Tyr Gly Gln Leu Phe
 545 550 555 560
 Arg Glu Asn Leu Tyr Tyr Gly Asn Asp Arg Ile Asn Thr Ala Asn Ser
 565 570 575
 Leu Ser Ala Ala Val Gln Ser Arg Ile Leu Asp Gly Ala Thr Gly Ala
 580 585 590
 Glu Arg Phe Arg Ala Gly Ile Gly Gln Lys Phe Tyr Phe Lys Asn Asp
 595 600 605
 Ala Val Met Leu Asp Gly Ser Val Gly Lys Lys Pro Arg Ser Arg Ser
 610 615 620
 Asp Trp Val Ala Phe Ala Ser Ser Gly Ile Gly Ser Arg Phe Ile Leu
 625 630 635 640
 Asp Ser Ser Ile His Tyr Asn Gln Asn Asp Lys Arg Ala Glu Asn Tyr

645 650 655
 Ala Val Gly Ala Ser Tyr Arg Pro Ala Gln Gly Lys Val Leu Asn Ala
 660 665 670
 Arg Tyr Lys Tyr Gly Arg Asn Glu Lys Ile Tyr Leu Lys Ser Asp Gly
 675 680 685
 Ser Tyr Phe Tyr Asp Lys Leu Ser Gln Leu Asp Leu Ser Ala Gln Trp
 690 695 700
 Pro Leu Thr Arg Asn Leu Ser Ala Val Val Arg Tyr Asn Tyr Gly Phe
 705 710 715 720
 Glu Ala Lys Lys Pro Ile Glu Val Leu Ala Gly Ala Glu Tyr Lys Ser
 725 730 735
 Ser Cys Gly Cys Trp Gly Ala Gly Val Tyr Ala Gln Arg Tyr Val Thr
 740 745 750
 Gly Glu Asn Thr Tyr Lys Asn Ala Val Phe Phe Ser Leu Gln Leu Lys
 755 760 765
 Asp Leu Ser Ser Val Gly Arg Asn Pro Ala Asp Arg Met Asp Val Ala
 770 775 780
 Val Pro Gly Tyr Ile Pro Ala His Ser Leu Ser Ala Gly Arg Asn Lys
 785 790 795 800
 Arg Pro

<210> 5

<211> 2016

<212> DNA

<213> *Neisseria meningitidis*

<400> 5

atgaaactcg aagcaagcaa gcaagcaagc aagcagaagt ttaaaaaatc atttattata 60
 agtctatttt ttctatttct ttatacctct cgcgttttgg ctgttgatta cgtttacgac 120
 aaaaccaagc tcaactgatga tgaaattacc cgcttaaaaa aactccgcga tagaaatagt 180
 gaattattgga aagaagaaac ttatcacata aaaagtaaca accgagttta tccaaacatt 240
 cccgcattat tccctaaaca tcctttcgat ccattcgaaa acatcaataa ttcaaaaagg 300
 atttcttttt atgacaaaga atacactgaa gattaccttg ttggttttgc tcaagggtta 360
 ggcgttgcaa aaagaaatgg ggaaacagaa aaaccaatac ggcaatattt taaggaatgt 420
 ttaaacactg ggaaatatag tgatgatact tgcaaatctc aacaatctat tcctacagta 480
 agaagtgata ttttcgcctt aaatacgaaa ataaaaata gccatatcaa cagcgaaatt 540
 ttcgctgtcg gtaattatac aaaattgatg tactcagccc aacatcattc ttttgggtca 600
 gagcatctct attccaattc agaattatct cttgacgttg ataactcaca cgttatcgga 660
 caaacgattg atttgggagc attagaatta acaaattctc tatgggaacc ccgttggaac 720
 tctaataattg attatttaat aacaaaaaat gctgaaattc gttttaaacac taaaagtga 780
 agtttactcg taaaagaaga ttatgctggc ggagctcggt ttcgttttgc ttacggtcta 840
 aaagataaag tccctgaaac accaatttta acttttgaaa aaaatataac tggcacatca 900
 gatattattt ttgagggaaa agcgttggat aattttaaac acctagacgg gcatcaaatt 960
 atcaaagtaa atggcacagc agataaacac gcattccgtc tttctggcaa acaccaaagg 1020
 ggaatttata cgctttcttt acaacaacgc ccagagggtt tttttaccaa agtgcaagaa 1080
 cgcgatgata ttgcgattta tgcacaacaa gccaagccg ccaatacctt attcgccttg 1140

cgttttaaagc acaaaaacag cgatatTTTT gaccgcactt taccgcgcaa aggcttgtgg 1200
 ttacgtgtga ttgacggaca ttccagccaa tgggtacaag gcaaaacggc accagtagaa 1260
 ggaaatcgta aaggcatata acttggtggc gatgttttct cattgcaaaa tcacaactat 1320
 caactttccg ttggcctaata gggcggacaa gcagaacaac gcagtacttt ccgcaaccca 1380
 gatacagaca atcttacaac gggaaatgtg aaaggccttg gtgcaggcgt ttacgccact 1440
 tggcatcagc ttcaggacaa acagacaggt gcgtatgcgg atagctgggt acaatatcaa 1500
 cgtttccgcc accgtatcaa cactgaagat ggtacagaac gttttacttc aaaaggtatt 1560
 actgcctcaa ttgaagcagg ttacaacgct ttattggcgg aacacgtaac taaaaagggc 1620
 aacagccttc gtgtttacct acaaccacag gcgcaattga cttatttggg ggtaaacgga 1680
 aaattcagcg atagcgaaaa tgcccacgtg aatttacttg gctctcgcca attacaaagc 1740
 cgagtgggcg ttcaagctaa agctcaattt gctttcacta atggcgtcac tttccaacca 1800
 tttgtttccg tcaattcaat ctaccaacaa aaacctttcg gggtagaaat ggacggagaa 1860
 cgtcgagtga taaacaacaa aaccgcgatt gaaagccaat taggcgttgc ggtaaaaatt 1920
 aaatctcact taactttaca agcaacattc aaccgccaaa caggcaaaca tcatcaagct 1980
 aaacaaggcg cattgaattt acagtggacg ttttaa 2016

<210> 6

<211> 671

<212> PRT

<213> *Neisseria meningitidis*

<400> 6

Met	Lys	Leu	Glu	Ala	Ser	Lys	Gln	Ala	Ser	Lys	Gln	Lys	Phe	Lys	Lys
1				5					10					15	
Ser	Phe	Ile	Ile	Ser	Leu	Phe	Phe	Ser	Ile	Leu	Tyr	Thr	Ser	Pro	Leu
			20					25					30		
Leu	Ala	Val	Asp	Tyr	Val	Tyr	Asp	Lys	Thr	Lys	Leu	Thr	Asp	Asp	Glu
		35					40					45			
Ile	Thr	Arg	Leu	Lys	Lys	Leu	Arg	Asp	Arg	Asn	Ser	Glu	Tyr	Trp	Lys
	50				55					60					
Glu	Glu	Thr	Tyr	His	Ile	Lys	Ser	Asn	Asn	Arg	Val	Tyr	Pro	Asn	Ile
65				70					75					80	
Pro	Ala	Leu	Phe	Pro	Lys	His	Pro	Phe	Asp	Pro	Phe	Glu	Asn	Ile	Asn
			85					90					95		
Asn	Ser	Lys	Arg	Ile	Ser	Phe	Tyr	Asp	Lys	Glu	Tyr	Thr	Glu	Asp	Tyr
			100					105					110		
Leu	Val	Gly	Phe	Ala	Gln	Gly	Leu	Gly	Val	Ala	Lys	Arg	Asn	Gly	Glu
		115					120					125			
Thr	Glu	Lys	Pro	Ile	Arg	Gln	Tyr	Phe	Lys	Glu	Cys	Leu	Asn	Thr	Gly
	130					135					140				
Lys	Tyr	Ser	Asp	Asp	Thr	Cys	Lys	Ser	Gln	Gln	Ser	Ile	Pro	Thr	Val
145				150					155					160	
Arg	Ser	Asp	Ile	Phe	Ala	Leu	Asn	Thr	Lys	Ile	Lys	Asn	Ser	His	Ile
			165					170					175		
Asn	Ser	Glu	Ile	Phe	Ala	Val	Gly	Asn	Tyr	Thr	Lys	Leu	Met	Tyr	Ser
		180						185					190		
Ala	Gln	His	His	Ser	Ile	Trp	Ser	Glu	His	Leu	Tyr	Ser	Asn	Ser	Glu

195 200 205
 Leu Ser Leu Asp Val Asp Asn Ser His Val Ile Gly Gln Thr Ile Asp
 210 215 220
 Leu Gly Ala Leu Glu Leu Thr Asn Ser Leu Trp Glu Pro Arg Trp Asn
 225 230 235 240
 Ser Asn Ile Asp Tyr Leu Ile Thr Lys Asn Ala Glu Ile Arg Phe Asn
 245 250 255
 Thr Lys Ser Glu Ser Leu Leu Val Lys Glu Asp Tyr Ala Gly Gly Ala
 260 265 270
 Arg Phe Arg Phe Ala Tyr Gly Leu Lys Asp Lys Val Pro Glu Thr Pro
 275 280 285
 Ile Leu Thr Phe Glu Lys Asn Ile Thr Gly Thr Ser Asp Ile Ile Phe
 290 295 300
 Glu Gly Lys Ala Leu Asp Asn Leu Lys His Leu Asp Gly His Gln Ile
 305 310 315 320
 Ile Lys Val Asn Gly Thr Ala Asp Lys His Ala Phe Arg Leu Ser Gly
 325 330 335
 Lys His Gln Lys Gly Ile Tyr Thr Leu Ser Leu Gln Gln Arg Pro Glu
 340 345 350
 Gly Phe Phe Thr Lys Val Gln Glu Arg Asp Asp Ile Ala Ile Tyr Ala
 355 360 365
 Gln Gln Ala Gln Ala Ala Asn Thr Leu Phe Ala Leu Arg Leu Asn Asp
 370 375 380
 Lys Asn Ser Asp Ile Phe Asp Arg Thr Leu Pro Arg Lys Gly Leu Trp
 385 390 395 400
 Leu Arg Val Ile Asp Gly His Ser Ser Gln Trp Val Gln Gly Lys Thr
 405 410 415
 Ala Pro Val Glu Gly Asn Arg Lys Gly Ile Gln Leu Gly Gly Asp Val
 420 425 430
 Phe Ser Leu Gln Asn His Asn Tyr Gln Leu Ser Val Gly Leu Met Gly
 435 440 445
 Gly Gln Ala Glu Gln Arg Ser Thr Phe Arg Asn Pro Asp Thr Asp Asn
 450 455 460
 Leu Thr Thr Gly Asn Val Lys Gly Phe Gly Ala Gly Val Tyr Ala Thr
 465 470 475 480
 Trp His Gln Leu Gln Asp Lys Gln Thr Gly Ala Tyr Ala Asp Ser Trp
 485 490 495
 Val Gln Tyr Gln Arg Phe Arg His Arg Ile Asn Thr Glu Asp Gly Thr
 500 505 510
 Glu Arg Phe Thr Ser Lys Gly Ile Thr Ala Ser Ile Glu Ala Gly Tyr
 515 520 525
 Asn Ala Leu Leu Ala Glu His Val Thr Lys Lys Gly Asn Ser Leu Arg
 530 535 540
 Val Tyr Leu Gln Pro Gln Ala Gln Leu Thr Tyr Leu Gly Val Asn Gly
 545 550 555 560
 Lys Phe Ser Asp Ser Glu Asn Ala His Val Asn Leu Leu Gly Ser Arg
 565 570 575

260 265 270
 Thr Ser Asp Asn Ala Arg Ile Arg Leu Asn Thr Lys Asp Glu Lys Leu
 275 280 285
 Thr Val His Lys Ala Tyr Gln Gly Gly Ala Asp Phe Leu Phe Gly Tyr
 290 295 300
 Asp Val Arg Glu Ser Asp Glu Pro Ala Leu Thr Phe Glu Gln Asn Val
 305 310 315 320
 Ser Gly Lys Ser Gly Val Val Leu Glu Arg Arg Pro Glu Asn Leu Lys
 325 330 335
 Thr Leu Asp Gly Arg Lys Leu Ile Ala Ala Glu Lys Ala Asp Pro Asn
 340 345 350
 Ser Phe Ala Phe Lys Gln Asn Tyr Arg Gln Gly Leu Tyr Glu Leu Leu
 355 360 365
 Leu Lys Gln Cys Glu Gly Gly Phe Cys Leu Gly Val Gln Arg Leu Ala
 370 375 380
 Ile Pro Glu Ala Glu Ala Val Leu Tyr Ala Gln Gln Ala Tyr Ala Ala
 385 390 395 400
 Asn Thr Leu Phe Gly Leu Arg Ala Ala Asp Arg Gly Asp Asp Val Tyr
 405 410 415
 Ala Ala Asp Pro Ser Arg Gln Lys Leu Trp Leu Arg Phe Ile Gly Gly
 420 425 430
 Arg Ser His Gln Asn Ile Arg Gly Gly Ala Ala Ala Asp Gly Arg Arg
 435 440 445
 Lys Gly Val Gln Ile Gly Gly Glu Val Phe Val Arg Gln Asn Glu Gly
 450 455 460
 Ser Arg Leu Ala Ile Gly Val Met Gly Gly Arg Ala Gly Gln His Ala
 465 470 475 480
 Ser Val Asn Gly Lys Gly Gly Ala Ala Gly Ser Tyr Leu His Gly Tyr
 485 490 495
 Gly Gly Gly Val Tyr Ala Ala Trp His Gln Leu Arg Asp Lys Gln Thr
 500 505 510
 Gly Ala Tyr Leu Asp Gly Trp Leu Gln Tyr Gln Arg Phe Lys His Arg
 515 520 525
 Ile Asn Asp Glu Asn Arg Ala Glu Arg Tyr Lys Thr Lys Gly Trp Thr
 530 535 540
 Ala Ser Val Glu Gly Gly Tyr Asn Ala Leu Val Ala Glu Gly Val Val
 545 550 555 560
 Gly Lys Gly Asn Asn Val Arg Phe Tyr Leu Gln Pro Gln Ala Gln Phe
 565 570 575
 Thr Tyr Leu Gly Val Asn Gly Gly Phe Thr Asp Ser Glu Gly Thr Ala
 580 585 590
 Val Gly Leu Leu Gly Ser Gly Gln Trp Gln Ser Arg Ala Gly Ile Arg
 595 600 605
 Ala Lys Thr Arg Phe Ala Leu Arg Asn Gly Val Asn Leu Gln Pro Phe
 610 615 620
 Ala Ala Phe Asn Val Leu His Arg Ser Lys Ser Phe Gly Val Glu Met
 625 630 635 640

Asp Gly Glu Lys Gln Thr Leu Ala Gly Arg Thr Ala Leu Glu Gly Arg
645 650 655
Phe Gly Ile Glu Ala Gly Trp Lys Gly His Met Ser Ala Arg Ile Gly
660 665 670
Tyr Gly Lys Arg Thr Asp Gly Asp Lys Glu Ala Ala Leu Ser Leu Lys
675 680 685
Trp Leu Phe
690